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Abstract 
Background: During herpes simplex virus type 1 (HSV-1) infection, the protein ICP0 
causes degradation of RNF168 during infection, preventing the ubiquitination of 
histones proteins and a subsequent DNA damage response to double strand breaks. Our 
laboratory has shown that during RSV infection in vitro, RSV replication as measured 
by RSV N gene expression increased considerably when SiRNA were used to knock 
down RNF168 gene. This suggests that RNF168 activity may be affected by RSV 
expression or act to limit RSV replication normally during infection as part of a host 
cell intrinsic antiviral defence.  Identifying and understanding the mechanism by which 
this occurs may be useful in the development of future drug therapies for RSV.  
Aims: To investigate the effect of RSV infection, interferon beta stimulation and 
polyI:C on RNF168 expression. To investigate how the duration of RSV infection 
affects the concentration levels of CXCL5. 
Methods: A549 cells were infected with RSV in a 24-well plate. Cells were also 
stimulated with IFN-! and the TLR3 ligand polyI:C. Real-time PCR for RSV N gene 
expression and Sandwich ELISAs for IL-6 and IL-8 were carried out to provide 
evidence that samples have been infected. Western Blotting was carried out to measure 
RNF168 expression. A Sandwich ELISA was applied to measure the concentration 
levels of CXCL5. 
Results: At a MOI of 1:1, 4 hours RSV infection suggested that there was an increase 
in RNF168 expression. This increase was not statistically significant (p=0.13). At 24 
hours after RSV infection, MOI 1:1 the level of RNF168 expression decreased in 
comparison to control but this decrease was not statistically significant (p=0.14). 
However, at a MOI of 0.025:1, 24 hours after infection, RNF168 expression increased 
in comparison to the control. This change was not significant (p=0.29). IFN-! 
stimulation for 4 hours suggested that higher concentrations of IFN-! increased 
RNF168 expression. This was not a significant change (p=0.17). IFN-! stimulation for 
24 hours suggested that higher concentrations caused a decrease in RNF168 expression 
in comparison to the control (p=0.6 for 100ng/ml). An increase in CXCL5 concentration 
in infected samples was seen at 6 hours in comparison to control, which supports 
previous proteonomic data results.  
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Conclusions: The results of this investigation suggest that RSV and IFN-! affects 
RNF168 expression at 4 and 24 hours. The preliminary experiment with polyI:C must 
be repeated to gain more evidence but suggests that TLR3 may be involved in 
regulating RNF168 expression. For the changes noted in RNF168 expression by RSV, 
IFN-! and polyI:C to be more significant, repeat experiment could be done to increase 
the samples size of data obtained.  The CXCL5 experiment will have to be repeated but 
supports previous laboratory findings that CXCL5 is involved in neutrophil recruitment. 
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1. Introduction 
1.1Respiratory Syncytial Virus Background  
1.1.1 Overview Respiratory Syncytial Virus  
Respiratory syncytial virus (RSV) is a major cause of viral lower respiratory tract 
infections (LRTI) in children worldwide (1-3). This virus contains a single stranded 
negative sense ribonucleic acid (RNA) consisting of an estimated 15,000 nucleotides. 
RSV is part of the family Paramyxoviridae and the subfamily Pneumovirinae (3, 4). 
However, this virus is not solely linked to paediatric respiratory illness, with significant 
respiratory symptoms commonly seen in the elderly and immunosuppressed. RSV 
disease severity tends to be worse in those with comorbidities such as asthma, Cystic 
Fibrosis (CF) and Chronic Obstructive Airway Disease (COPD) (3, 5, 6).  
1.1.2 Origins of RSV 
In Minneapolis during the year 1937 an outbreak of pneumonia occurred in two 
hospitals with 32 infants affected. Dr John Adams studied these cases, discovering the 
presence of cytoplasmic inclusions in bronchial epithelium of all dead babies. These 
findings led to Dr Adams suggesting that the outbreak was due to a virus. 
Approximately, two decades later in 1961 Dr Adams and his colleagues described a 
similar episode of lower respiratory tract infection (LRTI) in infants, this time 
identifying the virus that was to become known as RSV (7, 8).  
  
In 1956 a colony of chimpanzees were noted to be suffering with cold-like symptoms 
such as coughing, sneezing and mucopurelent discharge. Investigations carried out on 
throat swab samples taken from one of the chimpanzees identified a cryptopathic agent, 
which was later named “Chimpanzee Coryza Agent” (CCA). A laboratory worker who 
came into contact with the infected chimpanzees developed fever and frontal headache. 
The finding of positive CCA antibody titres in the worker indicated that this disease was 
transmittable between animals and humans (3, 9, 10). 
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A year later, Chanock and Finberg identified 2 agents in infants with lower respiratory 
tract disease indistinguishable from CCA. These agents were named Long and Snyder 
viruses. The Long agent was a CCA-like virus from an infant with bronchopneumonia 
and the Snyder agent was a CCA-like virus from an infant with bronchiolitis. It was 
noted that a prominent characteristic of both viruses was the production of giant cell 
syncytia in tissue culture. This lead to the suggestion that the agents identified in this 
study should be grouped together with CCA virus and named “Respiratory Syncytial 
Virus” (7, 9-12). 
 
1.1.3 Epidemiology of RSV 
 
According to the World Health Organisation (WHO) there are about 64 million cases of 
RSV with approximately 160,000 deaths per year worldwide (13). Other studies report 
that there 33.8 million new cases of RSV per year leading to 3.4 million hospital 
admissions and figures as high at 199,000 deaths per year (99% which occur in the 
developing world) (14, 15).  Laboratory reports, 4 weekly received by the Health 
Protection Agency (HPA) Colindale for England and Wales from 1991 to 2013 show 
that the number of reports of RSV is approximately 3200 in 2013 (Figure 1.1.1) (16). 
According to the HPA the most number of laboratory reports between 2012 and 2013 
was 750 for children< 1year old in England and Wales (Figure 1.1.2) (17). RSV is the 
leading cause of hospitalisations among infants, with those 1 month old at greatest risk 
of RSV hospitalisation. In comparison, up to 144,000 infants with RSV are hospitalised 
annually in the United States of America (USA) (13, 18-21). Admissions for RSV make 
up around 70% of bronchiolitis and 25% of pneumonia cases that have been 
hospitalised (13, 20, 22). 
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Figure 1.1.1: Laboratory reports due to RSV infection from 1991to 2013, 4 weekly 
(16). 
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Figure 1.1.2: Laboratory reports for RSV received by data of specimen and age in 
2012/13 for England and Wales (17).   
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Overall, studies have shown that males are more likely to be infected with RSV and 
hospitalised than females with the ratio at approximately 1.5:1 (23-26). Infants who are 
in higher socioeconomic groups have a lower chance of developing severe disease as 
they acquire primary RSV later (23). Pre-term infants tend to be a group associated with 
an increased risk of severe RSV-related illness and hospitalisation. The main factors 
contributing to an increased likelihood of hospital readmissions in pre-term children 
were those with lower gestational age, with siblings attending school and children with 
Chronic Lung Disease (CLD) (23, 27, 28).  
 
Apart from children, the elderly are also at risk of severe RSV infection. Information 
provided by WHO states that there are an estimated 14 000 to 62 000 RSV-associated 
hospitalisations of the elderly occurring annually in the USA. However, cases of RSV 
are rarely diagnosed in the elderly. This could be due to greater focus and importance 
being stressed on the effects of the virus in paediatric population (13, 29). In USA 
nursing homes, RSV ‘attack’ rates are approximately 5%-10% per year with a 2%-8% 
case fatality rate. This amounts to approximately 10,000 deaths per year among persons 
>64 years of age (13).  
 
The incidence in developing countries of RSV is more than twice that of industrialised 
countries with the virus accounting for a high proportion of Acute Respiratory 
Infections (ARI) in children. For example, studies in Brazil and Thailand suggest that 
RSV causes 30% of ARI cases in children between 1 and 4 years of age (13, 15). A 
study based in Kenya estimated that over half of severe infections occur between 6- 30 
months of age rather than< 6 months of age as previously thought, possibly because 
many children get reinfection with RSV (30).  
 
In the developed world, RSV bronchiolitis is the leading cause of hospitalisations for 
infants less than 1 year of age. In the winter season, RSV bronchiolitis is a common 
cause of admission to the Paediatric Intensive Care Unit (PICU) (31). Of the number of 
children hospitalised with RSV related bronchiolitis in the USA, 15-35% require 
admission to PICU with 9% requiring mechanical ventilation (32, 33). A recent study 
found that due to RSV the median length of PICU admission was 5 days with the 
median length of hospital stay being 9 days (34).  
!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%$!"()%&'(*+%,%$!!!!!!!!!!!!!!!!!!!!-.'/0!/$!1'/02!3(%0&'!!
! 56!
 
Outbreaks of RSV occur throughout winter in areas with temperate climates coinciding 
with outbreaks of influenza. In European countries, epidemics have been noted to occur 
from approximately mid-November to late March (13, 35-37). In comparison, high 
numbers of RSV cases are reported during the rainy season in tropical countries when 
the temperature drops (38).  
 
1.1.4 Risk Factors 
Some of the main predisposing factors of severe RSV disease include Chronic Lung 
disease (CLD), Congenital Heart Disease (CHD), neurological disorders, metabolic 
disorders, birth before 24 weeks gestation and immunodeficiency (Table 1.1). 
Bronchopulmonary Dysplasia (BPD), Cystic Fibrosis (CF) and severe asthma increase 
the risk of severe RSV infection. Due to their immune status and the structural 
prematurity of distal air spaces, children less than 2 months tend to be more susceptible 
to RSV than older children (Tables 1.1 and 1.2) (39-41).  
 
In developed countries, lack of breastfeeding, day care exposure, older siblings in 
households, male sex and birth during the RSV season are risk factors for RSV and 
severe RSV bronchiolitis (Table 1)(42). In comparison, the main risk factors for severe 
disease found in developing countries are indoor smoking pollution, crowding and 
malnutrition (Table 1.2) (37, 39, 43-45). A universal recognised risk factor for RSV 
infection is smoking. In particular maternal smoking was noted to be more harmful than 
paternal smoking. Studies have found that maternal smoking during pregnancy was 
noted to be an independent risk factor for reduced lung function and increased airway 
reactivity presenting during adulthood (39, 46).  
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Table 1.1: Conditions and resultant pathophysiology leading to increased risk of 
RSV in children (42) 
 
 
Children at risk of Severe RSV disease 
Condition Pathophysiology 
Premature birth Altered airway anatomy 
Absence of maternal antibody 
Chronic Lung Disease Bronchial hyper-responsiveness 
Reduced lung reserve 
Congenital Heart Disease Pulmonary hypertension 
Neuromuscular disease Decreased respiratory muscle strength and 
endurance 
Immune deficiency Decreased host defence 
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Table 1.2: Main Risks Factors contributing to Severe RSV infection (37, 39, 43-45) 
 
Main Risk Factors contributing to Severe RSV infection 
Social Determinants:  
• Infant environmental smoke exposure. 
• Maternal exposure to environmental tobacco smoke during pregnancy.  
• Maternal tobacco use during pregnancy. 
 
Significant Illness: 
• Severe neurological disorders.  
• Severe metabolic disorders. 
• Chronic lung disease (CF, BPD, Asthma). 
• Haemodynamically significant Congenital Heart Disease (CHD) 
• Disorder of cellular immunity.  
 
Environmental Factors:  
• Malnutrition  
• Presence of siblings  
• Crowded living conditions  
• Low socioeconomic status  
• Day care exposure  
• Outdoor air pollution 
• Indoor smoke (due to burning wood or coal) 
 
 
Other: 
• Male sex 
• Current weight <5kg 
• Premature birth (before 35 weeks gestations) 
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1.1.5 Clinical Features  
The symptoms of RSV infection range from mild cold-like symptoms to those of severe 
pneumonia or bronchiolitis. Upper respiratory tract symptoms such as coryza, rhinitis 
and coughing have been known occur in patients. Low-grade fever and rhinorrhoea is 
usually present with some children developing otitis media. Children who suffer with 
more severe infection display signs of nasal flaring, grunting and intercostal recessions 
(47-49). Infants often have an increased respiratory rate and hyperinflated chest because 
of increased air trapping. Cases of bronchiolitis can result in severe hypoxia and acute 
respiratory failure (48, 50).    
1.1.6 Investigations  
RSV infection can be tested for using the following methods (51, 52):  
• Serology  
• Cell culture  
• Direct immunofluorescent antibody tests  (DFA) 
• Enzyme linked immunoassays  
• Nucleic acid amplification (using PCR) 
• Rapid antigen detection testing (RADT) 
 
In acute illness, serological testing and cell culture are not useful. Cell culture also 
requires precise collection and processing techniques and is time consuming. In 
comparison DFA and PCR require specialist equipment and staff, making it difficult to 
provide timely results 24 hours a day. Rapid antigen detection testing is the most 
frequently used test for RSV in clinical settings.  This is because it is inexpensive, easy 
to perform and the results are available quickly in comparison to other tests (53, 54). 
 
Nevertheless, in comparison to laboratory-based tests such as DFA, rapid antigen 
detection has proven to be less sensitive. In comparison to RT-PCR, RADT has only 
50-85% sensitivity. It should be noted that the clinical utility and overall performance of 
rapid immunoassays depends on many factors. These include method of specimen 
collection, time of specimen collection in relation to onset of symptoms and patients 
age. Additional factors that affect rapid performance detection and utility include 
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subjective visual interpretation of results and a low positive predictive value when 
testing is performed during periods of low disease prevalence (52, 54).  
 
Other clinical investigations can be used to provide supporting evidence for RSV 
infection such as arterial oxygen saturation, respiratory rate and chest X-rays (Figure 
1.1.3) (55).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.3: X- ray showing hyperinflation in RSV patient with bronchiolitis. 
However, diagnosis tends to be made based on clinical picture supported by RSV 
detection. This image was kindly provided by Dr P McNamara 
 
1.1.7 Prevention and Prophylaxis  
1.1.7.1 Sterilisation and barrier methods 
Simple methods such as hand washing can be applied with regards to preventing the 
spread of RSV infection. This virus in known to be mainly transmitted by hand to hand 
contact instead of droplet inhalation. Hands should be washed before and after contact 
with a patient or any contaminated objects (43, 56, 57). The mother must avoid smoking 
around children and during pregnancy. It has been suggested that breastfeeding can 
produce benefits with regard to a child’s general health with lipids in human milk 
displaying some antiviral activity (58).  The key issue with vaccination is developing a 
cost-effective vaccine with vaccination viewed as cost-effective only with patients at 
increased risk of severe RSV infection (59). 
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1.1.7.2 Palivizumab 
Palivizumab (trade name Synagis) is a humanised murine monoclonal antibody directed 
against RSV. It is the first monoclonal antibody to provide immune prophylaxis of 
infectious disease in humans (43, 57, 60, 61).  However, it is not widely used as it is 
only given to high risk infants in 5 separate monthly jabs and is expensive (62). 
 
Palivizumab binds to the RSV fusion (F) protein at a highly conserved region between 
amino acids 258 and 275 known as antigenic site A. Palivizumab prevents RSV from 
fusing with the respiratory epithelial cell membrane, preventing virus entry and 
therefore replication (43, 60, 61, 63).  
 
In the UK, palivizumab is used as a preventative measure against RSV infection in 
children from the following three high-risk groups. (43):   
1) Infants born before 35 weeks gestation.  
2) Infants with chronic lung disease.  
3) Infants born with haemodynamically significant Congenital Heart Disease.  
 
Palivizumab is given as 5 monthly intramuscular injections (15 mg per kg). Some 
children may receive fewer than 5 injections but no more than 5 should be administered. 
Despite palivizumab’s use as a primary means of prophylaxis, no benefit has been seen 
in terms of RSV mortality rate. Nevertheless, significant benefits are seen in RSV 
prophylaxis by the reducing the number of hospitalisations (43, 64).  
 
A recent study has found that palivizumab treatment resulted in a significant reduction 
in wheezing days in preterm infants during the first year of life (65). Therefore, it could 
be said that RSV offers some benefit in preventing post RSV respiratory symptoms. 
Ribavirin is the only drug licensed for therapy of RSV infection but its toxic effects, 
relatively high cost and nonspecific anti-RSV activity limit its clinical use (66).  
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1.1.8 Management  
 
The management of hospitalised cases of severe acute bronchiolitis consists of 
supportive care, such as nasal suction, nasogastric or intravenous fluids, supplemental 
oxygen, and nasogastric feeding. The management of bronchiolitis in children is 
provided by UK Signs the National Clinical Guidelines for Bronchiolitis in Children 
(67).  
 
 
Nasal suction is used to clear secretions in infants hospitalised with acute bronchiolitis 
who exhibit respiratory distress due to nasal blockage. For infants with acute 
bronchiolitis who cannot maintain oral intake or hydration nasogastric feeding should 
be considered. Infants suffering with cyanosis or severe respiratory distress or have 
oxygen saturation level " 92% should receive supplemental oxygen by nasal cannula or 
facemask. Previous research has identified that there is no significant benefit of 
nebulised epinephrine, inhaled corticosteroids, systemic steroids, leukotriene receptor 
antagonists and chest physiotherapy for the treatment of acute bronchiolits is infants 
(67).  Alder Hey Children’s Hospital has a specific care management pathway for the 
management of bronchiolitis in children (Figure 1.1.4).  
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Figure 1.1.4: Care management pathway for children suffering from bronchiolitis 
at Alder Hey Children’s hospital provided by Dr Paul McNamara.  
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1.1.9 RSV in Adults  
All adults get RSV infection on mean every 18 months to 3 years, they will often be 
asymptomatic. Clinical feature include nasal congestion, cough, wheeze and low-grade 
fever. It is difficult to diagnose RSV infection in adults because viral cultures and 
antigen detection are insensitive due to low viral titres in nasal secretions. Treatment of 
RSV is largely supportive. Ribavarin and gamma immunoglobulin are associated with 
increased survival in the immunosuppressed. Infection control by good hand hygiene 
and gloves are effective preventative measures (49, 68). 
 
1.2 Virology  
1.2.1 Key Components of RSV Virus  
 
RSV has a RNA genome and is composed of 15,000 nucleotides. RSV contains 10 
genes, which encode 11 viral proteins (3, 69). There are 11 proteins because 2 
overlapping reading frames in M2 mRNA yield 2 distinct matrix proteins M2-1 and 
M2-2.The attachment (G) protein is involved in host cell attachment and the fusion (F) 
protein is involved in fusion and cell entry. The SH protein is not involved in either of 
these processes. The other 5 structural proteins are nucleocapsid (N), large (L) 
polymerase protein, phosphoprotein (P), matrix (M) and M2-1 and the 2 non-structural 
proteins NS1 and NS2 (Figure 1.1.5). It is not know M2-2 functions in mature virus 
assembled particles (3, 69-71). The details about the functions of these proteins are 
provided (Figure 1.1.6). 
 
 
 
 
 
 
 
 
 
Figure 1.1.5: Basic RSV genetic structure and 11 viral proteins (3). 
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Figure 1.1.6: Negatively stained electron micrograph of budding RSV virions. F 
indicates filamentous cytoplasmic structures thought to be nucleocapsids and V 
indicates a budding virion. The locations of viral proteins in the virion, and their known 
functions are indicated (69). 
 
The following overview of function of viral proteins is taken from the journal article 
Progress in understanding and controlling respiratory syncytial virus: still crazy after 
all these years (69). RSV transcription and RNA replication follow the 
Mononegavirales model. The polymerase enters the genome at the 3? end, which begins 
with a 44-nucleotide leader region. Genes are transcribed in succession guided by short 
gene-start and gene-end signals to produce individual messenger RNA (mRNAs). 
During RNA replication, the polymerase yields a complete positive sense replicative 
intermediate called the antigenome, which serves as the template for producing progeny 
genomes (69, 72, 73). 
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RNA synthesis is carried out by the large L polymerase protein, which performs mRNA 
capping and polyadenylation (3, 74). The actual template is viral ribonucleoprotein 
(RNP) or nucleocapsid, a complex of viral genomic or antigenomic RNA tightly bound 
by N protein. This stops degradation of these RNAs. It has been suggested that 
encapsidation reduces detection of these RNAs by pattern recognition receptors in the 
host cell (69, 73). 
 
The P protein is a homotetramer, which is known to interact with N, L, and M2-1 and is 
an essential co-factor of the polymerase (3, 75). Though much shorter than other 
Paramyxoviridae counterparts, RSV P has similar activities. The C-terminus of P 
interacts with the C-terminus of N to open the RNP structure so the polymerase, 
tethered by P, can reach bases in the viral RNA. The P protein also interacts with newly 
synthesized N to prevent illegitimate assembly of the latter and to deliver it to the 
nascent chain during genome replication. Promoter clearance and chain elongation by 
the viral polymerase during transcription seem to be dependent on the P protein (69, 73, 
75). 
 
 
M2-1 and M2-2 are RNA synthesis factors. M2-1 is a transcription processivity factor. 
When M2-1 is absent, transcription terminates prematurely and non-specifically within 
several hundred nucleotides. M2-1 is a homotetramer that binds to the P protein. It is 
suggested that P associates with soluble M2-1 and delivers it to the RNA template. The 
other factor involved in RNA synthesis, M2-2 protein, is a small, non-abundant species 
that accumulates during infection and appears to shift RNA synthesis from transcription 
to RNA replication (69). M protein lines the inner surface of the viral envelope. M has a 
central role in budding and may silence viral RNA synthesis in preparation for 
packaging (69, 76).  
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The NS1 and NS2 proteins both interfere with the induction of interferon beta (IFN-!)  
(77, 78). The NS1 protein has the greater effect on inhibiting IFN induction. These 
proteins impede the signal transduction pathway leading to up-regulation of IFN-! at 
multiple steps: NS2 binds to the cytoplasmic receptor RIG-I; either protein mediates a 
decrease in TNF receptor-associated factor 3 (TRAF3); and NS1 mediates a decrease in 
IKK?. The NS proteins strongly suppress IFN-induced signal transduction from its 
receptor through the Janus Tyrosine Kinase (JAK)/STAT pathway.  This suppression is 
mediated by proteosomal degradation of the signal transducer and activation of 
transcription (STAT) 2 by NS2. However there also is evidence that NS1 can assemble 
ubiquitin ligase enzymes to target STAT2 (69, 78-80).  
 
1.2.2 Key Proteins in RSV Infection 
There are three main surface lipid envelope glycoproteins encoded by RSV that are 
components of the virion: fusion protein F, attachment protein G and small hydrophobic 
protein SH (69, 81, 82).  
 
1.2.2.1 Fusion Protein (F) 
The F protein is made up of 574 amino acids its inactive form. The fusion of both viral 
and cell membranes is promoted by the F protein, resulting in the transfer of viral 
genetic material (48, 83). The importance of this protein has been highlighted by the 
ability of the virus to attach to a cell with the F protein present but the G and SH 
proteins absent. When a RSV virus particle attaches to the target cell, the F protein 
becomes activated by an unknown mechanism. This activation causes the F protein to 
undergo conformational changes, allowing the fusion peptide of the F protein to be 
inserted into the plasma membrane of the target cell. As a result, infected cells express 
RSV F protein on the their plasma membrane and this mediates cell to cell fusion 
resulting in multinucleate syncytia formation which is the characteristic feature of RSV 
infection (48, 69, 81, 84, 85).  
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1.2.2.2 Attachment Protein G 
G proteins consist of about 299 amino acids and are an essential component for viral 
attachment to the cell. It is naturally expressed as membrane bound and anchored forms. 
This protein is responsible for the differences between the two major RSV strains A and 
B. This is due to the protein’s antigenic variability, with the G protein of the A and B 
strains differing by 47%. The G proteins of the same strain differ by 20% (48, 69, 83, 
86). 
 
RSV has developed multiple mechanisms to evade host immune response. The G 
protein, which is a RSV antigen that induces neutralising antibodies, is heavily 
glycosylated and this interferes with antibody recognition. The G protein can be 
secreted in truncated form, which acts as a decoy for neutralising antibodies (Figure 
1.1.7) (3).  
 
 
 
Figure 1.1.7: Viral G protein evasion strategies (3). 
 
 
1.2.2.3 Small Hydrophobic Transmembrane Protein SH 
The small hydrophobic (SH) transmembrane protein is 64 amino acids, type 2 integral 
membrane protein. The role of the protein is unclear but it is known that this protein 
does facilitate fusion. In infected cells most SH protein accumulates at the membrane of 
Golgi complex but is also found in the plasma membrane and the endoplasmic 
reticulum(48, 87). The SH protein has the ability to permeabilise membranes. Recent 
studies have shown that the SH protein functions as a viroporin which as act as a proton 
or ion channel, enhancing the membrane permeability of the host cell (48, 69, 87-90).  
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1.3 Immune Response 
 
Previous work on RSV has suggested that immunological mechanisms could be the key 
to the severity of RSV bronchiolitis in infancy (48). This is because the disease is most 
prevalent when the infant is least immunologically mature despite the possession of 
maternally derived specific RSV antibody. The immunological response to RSV 
infection in humans can be divided into innate and adaptive (48, 91).   
1.3.1 Innate Immunity  
 
The innate immune system is the body’s first line and earliest phase of defence (92). It 
consists of a cellular response and an activation of mechanisms that defend the host 
from a wide range of organisms in a generalised rather than pathogen specific manner. 
Pulmonary surfactant, which is made up of a layer of phospholipids together with 
several surfactant proteins is one example of this first line of innate defence in the 
airway. Surfactant protein A has been shown in vitro to neutralise RSV by binding to F 
protein but not G protein (32, 48).  
 
Pattern recognition receptors (PRRs) are involved in the recognition of microbial 
products by host cells and initiate an innate immune response. There are 3 types of 
PRRs associated with RSV, which are toll-like receptors (TLRs), retinoic acid inducible 
gene (Rig-1)-like receptors and nucleotide-binding oligomerisation domain (NOD)-like 
receptor (NLRs). Rig-1 like receptors are critical sensors of viral infection initiating an 
interferon beta production in response to RSV. NOD-like receptor are also involved in 
an antiviral response through interferon production (93).   
 
The TLRs have a central role in innate immunity, initiating an innate immune response 
through the production of interferon beta, proinflammatory cytokines and cause 
neutrophil migration. TLR2, TLR3, TLR4, and TLR7 are linked to RSV infection. 
TLR2 acting as a functional receptor of RSV and TLR4 specifically detects the RSV F 
protein. TLR7 detects singles stranded RNA (ssRNA) and therefore would be involved 
in the detection of RSV which is a negative stranded ssRNA. TLR3 is responsible for 
recognizing viral double stranded RNA (dsRNA), which in this case will be the dsRNA, 
generated during the RSV replication cycle (93, 94).  
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Interleukin-8 (IL-8) and interleukin-6 (IL-6) are proinflammatory cytokines produced 
by respiratory epithelial cells in response to RSV infection (48, 95). Raised levels of IL-
8 are seen in serum and bronchoalveolar lavage samples from infants ventilated with 
RSV bronchiolitis (96). Serum levels of IL-6 are increased during RSV infection. IL-6 
and IL-8 have important roles in initiating neutrophil and macrophage chemotaxis (48, 
97, 98).  
1.3.2 Interferon in Innate Immunity  
1.3.2.1 Interferon role in antiviral defence mechanism 
Type 1 interferon (IFN), a soluble cytokine and represents one of the first major barriers 
to infection in terms of innate immunity, exhibiting potent antiviral effect. Interferon 
has a significant role in antiviral defence by inhibiting replication (79, 80, 99). Type 1 
IFNs initiate a bimodal response, which firstly involves the secretion of IFNs in 
response to detection of an invading virus. Secondly IFNs act in a paracrine and 
autocrine manner to induce 300 IFN-stimulated genes (ISGs), which ultimately leads to 
the production substances, that disruption of viral replication (Figure 1.1.8).  As a result, 
of the protective effects of IFNs, viruses have adapted to form strategies for overcoming 
anti-viral responses (100).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.8: The role of interferon stimulating genes. Viruses are detected by PRRs, 
which leads to activation of interferon regulatory factors (IRFs) and the transcriptional 
induction of IFNs. The IFNs signal through the JAK/STAT pathway inducing ISG 
production. ISGs can also be induced by some IRFs acting through an IFN independent 
pathway (thin blue line).  
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Some ISGs block viral replication whilst other can actually promote it in some viruses. 
Subsets of ISGs are a component of the interferon pathway and promote its signalling 
(red dotted arrows).  ISG induces several negative regulatory factors to target PRR, 
JAK/STAT and IRFs to dampen down the response (thin red lines) (100, 101).  
 
 
1.3.2.2 Viral recognition and Interferon response pathways  
Pathogen associated molecular patterns (PAMPs) present on the virus particles are 
recognised by a cell’s pattern recognition receptors (PRR) in a biphasic type 1 
interferon response (80, 102). The PRRs involved include Toll-like receptors (TLRs), 
which detect viral components such as nucleic acids and glycoproteins. TLRs act 
through toll interleukin-1 receptor (TIR) domains to recruit TIR-containing adaptors 
such as TIR-domain-containing adapter-inducing interferon beta (TRIF), Mal and 
TRIF-related adaptor molecule (TRAM). This leads to the activation of NF-"B (nuclear 
factor kappa-light-chain-enhancer of activated B cells) and interferon regulatory factor 
3 (IRF3), which ultimately leads to interferon production (80). 
 
 
The second class of PRRs is retinoic acid inducible gene – 1 (RIG-1)-like receptor 
(RLR) family, including RIG-1 and melanoma differentiation-associated gene 5 
(MDA5). The function of RLRs is to detect cytoplasmic double stranded RNA 
(dsRNA). They interact with adaptor mitochondrial antiviral signaling proteins (MAVS) 
and activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and 
IRF3. In RSV the N protein is responsible for inhibiting MDA5 and MAVS (80, 103).   
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1.3.2.3 IFN Expression due to Transcription Factor Activation  
 
If a virus is sensed by a PRR, then the transcriptional factor activation occurs leading to 
interferon production (Figure 1.1.9) (80).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.9: Transcription activation leading to IFN production. Detection of viral 
components by PRR leads to activation of transcriptional factors. (a) NF-"B is held in 
an inactive cytoplasmic complex due to the inhibitor I"B alpha. I"B alpha is degraded 
upon viral recognition resulting in its degradation. This frees the NF-"B to translocate 
to the nucleus where it binds to IFN-promoter. (b) When the virus is detected, kinases 
phosphorylate IRF3 leading to its dimerisation and translocation. (c) Low level of IFN 
production induces IRF7 expression leading to its phosphorylation by kinases, 
heterodimerization with IRF3, nuclear translocation and increased IFN expression. (d) 
When the virus is detected, stress activated members of the mitogen-activated protein 
(MAP) kinase family phosphorylated nuclear ATF2/cjun leading to activation of this 
complex. The combined binding of NF-KB, IRF3 and IRF7 leads to full expression of 
type 1 IFN genes (80). 
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1.3.2.4 Interferon Signaling 
The second phase of biphasic interferon response is where interferon binds to its 
interferon alpha/beta receptor (IFNAR) and activates ISG induction (Figure 1.2.1) (80).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.1: Interferon signalling resulting in ISG expression. When interferon is 
secreted, it binds to the cell surface receptor interferon-#/! receptor (IFNAR). Kinases 
are activated, resulting in the phosphorylation of signal transducer and activation 
transcription (STAT) 1 and STAT2. This results in the formation of a heterotrimeric 
complex containing interferon regulatory factor 9 (IRF9) which is also referred to as 
IFN stimulated gene factor 3 (ISGF3).  The binding of ISGF3 to promoters of ISGs 
leads to their transcriptional activation. The collective actions of hundreds of ISGs 
induced by IFN inhibit the spread and replication of virus (80).  
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%$!"()%&'(*+%,%$!!!!!!!!!!!!!!!!!!!!-.'/0!/$!1'/02!3(%0&'!!
! 74!
1.3.3 Adaptive Immunity  
 
Adaptive immunity can be divided into humoral and cell-mediated responses. (48). 
1.3.3.1 Humoral Immunity 
Humoral response to RSV infection occurs resulting in the production of antibodies. 
The production of serum neutralising antibodies is higher in older children and adults in 
comparison to children. Antibodies are produced in response to F and G proteins, which 
acts as RSV antigens. The antibodies produced are IgE, IgM, IgA and IgG (48).  IgM is 
produced 5 days post infection and stays elevated for around several weeks after 
infection. IgG is produced 10 days after infection and remains elevated for several 
months. IgA in adults is elevated 3 days post infection. There has been evidence that 
IgE levels are affected in bronchiolitis (3, 104). 
1.3.3.2 Cell-mediated Immunity   
The relationship between T cells and RSV infection with respect to immune response, 
immunomodulation and immunopathology is complex. A basic overview has been 
provided  (Figure 1.2.2) (14).  There are four main types of helper T cells are Th1, Th2, 
Th17 and T regulatory (regs). These types of T cell all function in response to RSV 
infection (Figure 1.2.3). IFN-$, IL2, TNF-# and IL-4, IL-5, IL-10, IL-13 are released as 
part of TH1 and TH2 response to an incoming pathogen (14). 
 
Human observational studies implicate T cells in viral clearance. In children with severe 
infection, accumulation of CD8+ antigen-specific T cells in the peripheral blood and 
airways, peaking at around nine days after symptom onset is seen. A prospective study 
examining RSV infected children under the age of five where individuals were 
immunocompromised due to chemotherapy or had primary immunodeficiencies 
affecting T cell function were found to shed virus at higher levels for several months, 
compared to the 7–21 days in normal children and suffered more severe disease. This 
study provides evidence suggesting that T cells are involved in viral clearance (3, 14, 
104). 
 
 
Dendritic cells (DC) are major antigen presenting cells which and act as an interface 
between the innate and adaptive arms of the immune system (105).  
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RSV infected human DCs have been found to impair CD4+ T cell proliferation and 
have been shown to inhibit the production of cytokines, including IFN gamma.  The 
mechanism for this phenomenon is currently unclear. RSV infection of DCs renders 
them unable to activate T cells as a result of failure to assemble the immunological 
synapse required for antigen recognition (14, 105) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.2: Role of T cells in RSV clearance, protective immunity and 
immunopathology. RSV infects respiratory epithelial cells, inhibiting type I 
interferons. Direct infection of dendritic cells also causes interferes with antigen 
presentation, leading to impaired T cell function, reduced viral clearance and memory 
formation. T cell subsets that enhance immunopathology but which may be limited by 
regulatory T cells (Treg) (14).  
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Several T cell subsets have been implicated in the immunopathology seen during RSV 
infection. These include nonclassical T cells, such as #$ T cells. Increases in #$ T cells 
are associated with increased disease severity. These cells make Th1-like cytokines 
early post infection, but more IL-4, IL-5 and IL-10 at later time-points (14). 
 
 
It has been shown that Th17 cells may play a role in regulating inflammation in the 
RSV-infected lung. This CD4+ T cell subset is characterised by production of IL-17, a 
cytokine that induces chemokine production by respiratory epithelial cells and resultant 
leukocyte infiltration.  In vitro, bronchial epithelial cells infected with RSV cause the 
differentiation of peripheral blood lymphocytes to Th2 and Th17 phenotypes. Members 
of the IL-17 family are induced following RSV infection and cause neutrophil 
recruitment to the airway, mucus production, and impairment of viral clearance as seen 
in mouse models. Th17 cytokines have also been found to be critical for RSV 
associated airway hyperresponsivness (14, 106).  
 
The control of T cell-associated autoimmunity and immunopathology is mediated by 
the regulatory T cell (Treg) subsets, in RSV disease. Tregs are essential modulators of 
the adaptive immune response, making up 5–10% of CD4+ T cells in the mouse and 
regularly characterised by the expression of the transcription factor FoxP3. Absence of 
CD4+ FoxP3+ Treg cells in both mice and humans leads to autoimmunity, and 
defective or suboptimal Treg function during RSV infection may cause 
immunopathology. In RSV-infected mice, Tregs proliferate and accumulate in the 
lungs, upregulating activation markers and CTLA-4 in RSV infected mice.. Tregs lead 
to anti-inflammatory cytokines such as IL-10 being produced in abundance by this 
subset, which also limits pulmonary inflammation. Studies have concluded that Tregs 
are essential for the control of mucosal inflammation during RSV infection. Thus, Tregs 
appear to limit immunopathology in RSV disease and may provide new opportunities 
for interventions to limit inflammatory disease (14). 
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1.4 Purpose of Study  
 
1.4.1 RNF168 Investigation 
1.4.1.1 Ubiquitination  
 
Ubiquitination regulates a host critical cellular function often through mediating the 
selective degradation of master regulatory proteins by proteasomes by labelling these 
proteins with ubiquitin (Ub) (107). Some of the processes regulated by the ubiquitin/ 
proteasome dependent proteolysis include cell cycle progression, induction of 
inflammatory response and antigen presentation. Apart from the degradation of 
proteins, ubiquitin tagged proteins are involved in ribosomal function, post replication 
DNA repair and the function of certain transcription factors.  
 
Ubiquitin (Ub) is a 76 amino acid polypeptide chain. A cascade of enzymes is required 
for the ubiquitination reaction. Ubiquitination usually results from a formation of a 
bond between the C terminus of ubiquitin and e-amino group of substrate lysine residue. 
The reaction requires sequential actions of three enzymes.  
 
The activating enzymes (E1), which contain an active-site cysteine attaches to the 
ubiquitin carboxy-terminal glycine through a reactive thioester bond (108). The 
conjugating enzyme (E2) transiently carries the activated ubiquitin molecule as thiol 
ester.  The ligase enzyme (E3) transfers the activated ubiquitin from E2 to the substrate 
(or ubiquitin) and catalyses the attachment of Ub to a lysine in the target protein. This 
mechanism involving the three enzymes are responsible for all known ubiquitination 
reactions and are independent of every various process that each substrate bound 
ubiquitin will mediate (Figure 1.2.2) (108-112).  
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Figure 1.2.3: Biochemical reactions of ubiquitination. This image was taken from 
Hokkaido University Graduate School of Medicine website (113).  
 
Monoubiquitination (monoUb) is where a single Ub molecule attaches to a substrate. 
Ub contains seven lysine residues that can themselves be a substrate of ubiquitination, 
giving rise to polyubiquitinated (polyUb) chains that according to the type and position 
of inter chain linkages are recognised differently by the cell. For example, polyubiquitin 
chains built via lysine 48 (K48) have been extensively characterised (107, 108, 114). 
 
The E3 ligases are an enzymatic family consisting of 600 proteins. They are the final 
enzymes of the in the ubiquitination conjugating cascade and have substrate specificity. 
Two known large groups of E3 are Homologous to the E6-AP Carboxyl Terminus 
(HECT) domain and Really Interesting New Gene (RING) finger domain (107, 115). 
RING E3 ligases are specified in over 600 human genes and play a critical role in 
controlling many critical cellular processes and have been implicated in multiple human 
diseases (116).   
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1.4.1.2 RING Finger E3 Ligase 
 
The basic sequence of the canonical Really Interesting New Gene (RING) is Cys-X2 -
Cys-X(9-39) -Cys-X(1-3) -His- X(2-3) -Cys-X2 -Cys-X(4-48) -Cys-X2 –Cys as seen in 
(Figure 1.2.3). RING domains function as enzyme E3 ligase in the process of 
ubiquitination, binding to ubiquitin-conjugating enzymes and promoting direct transfer 
of ubiquitin to the substrate (115-117).  
 
Figure 1.2.4: Primary sequence and 3-dimensional structure of the RING finger 
domain. (a) Basic sequence for canonical RING (b) Three dimensional structure of the 
RING finger where it is shown that cysteine and histidine residues are buried within the 
domains core where the overall structure is maintained by binding to zinc atoms (116, 
117) 
 
 
RING E3 ligases bind both substrate and E2–ubiquitin (E2–Ub) thioester. In terms of 
the E2-E3 association RING ubiquitin ligases should be considered to be bisubstrate 
enzymes that have two substrates and two products. The substrates can be are the lysine 
residue on the target protein (substrate) and the E2 thioesterified with ubiquitin 
(E2~Ub). The two products are the target protein linked to ubiquitin and the discharged 
E2 (1.2.4) (116, 117).  
 
>!
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Figure 1.2.5: The reaction cycle of RING E3, association between E2 and E3. (a) 
Unliganded E3. (b) The E3 bind to the substrate and E2~Ub. The order in which they 
bind is not predetermined. (c) Ubiquitin is transferred from E2!Ub to the substrate, 
which becomes monoubiquitinated. (d) To initiate further ubiquitination, the E2 must 
dissociate to allow a fresh molecule of E2!Ub to bind. (e) The newly recruited E2!Ub 
attaches to E3. (f) The E2 transfers its Ub to the substrate, which becomes 
diubiquitinated (116). 
 
 
After the ubiquitin molecule has been transferred to the target protein, a sequential 
reaction can take place where more ubiquitin molecules can be transferred to the same 
substrate resulting in the formation of a polyubiquitinated chain (Figure 1.2.5) (116, 
118). Therefore, the RING E2-E3 complexes can monobiquitinate a substrate lysine or 
synthesise polyubiquitin assembled through different lysine residues of ubiquitin. These 
modifications have a wide range of effects including protein function, structure, and 
assembly as well as proteasome-dependent proteolysis (116, 119). 
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Figure 1.2.6: Polyubiquitination of the substrate. Addition of Ub to the substrate by 
different E2s (ia, ib, ic, id) resulting in a polyubiquitin chain (116).  
 
After the E2 has transferred the ubiquitin molecule to E3, it must be recharged with 
ubiquitin from E1 (Figure 1.2.6) (116). 
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Figure 1.2.7: The process by which E2 is used and recycled. (a) The E2 transfers Ub 
to the substrate. (b) E2 has to dissociate from RING E3. (c) E2 binds to E1 to gain 
another ubiquitin molecule. (d) The E2 returns to the cellular pool of E2~Ub. (e) The 
spent E2 makes way for a fresh molecule from this cellular pool. (f) The second cycle of 
ubiquitin transfer begins (116).   
 
RING fingers are unique in terms of their action in comparison to other big groups of 
E3 ligase such as Homologous to the E6-AP Carboxyl Terminus (HECT). RING E3 
ligases effect the direct transfer of ubiquitin from E2~Ub to substrate (Figure 1.2.8) 
(116). 
 
 
 
 
 
 
 
 
Figure 1.2.8: Comparison between HECT (a) and RING (b) E3s (a) HECT E3s have 
a conserved cysteine residue, which accepts ubiquitin from E2!Ub forming an E3!Ub 
thioester. Ubiquitin is transferred from this covalent E3 intermediate to substrate. (b) In 
comparison, RING E3s affect the direct transfer of ubiquitin from E2!Ub to substrate 
(116) 
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The protein RNF168 belongs to the RING finger family of E3 ubiquitin ligase (120). 
There is evidence to suggest that RNF168 plays a role in the intrinsic antiviral defence 
of cells from herpes simplex type1 viral infection (HSV-1). It is important to understand 
the structure and function of RING E3 ligases and specifically RNF168 as this could 
provide useful information about how RNF168 could play similar role against RSV 
infection (116, 121-123). 
 
 
1.4.1.3 RNF168 Background  
 
RNF168 is a 571 long amino acid long protein containing a RING finger motif, two 
Motifs Interacting with Ub (MIU) domains and three putative nuclear localisation 
signals (109). The two MIU domains are responsible for binding to ubiquitinated 
proteins. This is shown in recent studies where inactivation of two MIU domains 
resulted in a reduced binding of RNF168 to ubiquitinated proteins. The basic structure 
of the RNF168 depicting the two MIU domains is shown below (Figure 1.2.9) (109, 
124-126). 
 
Figure 1.2.9: RNF168 structure showing the two MIU domains (126).  
 
The RING finger protein RNF168 is a relatively new ubiquitin E3 ligase that has a role 
as a chromatin modifier through ubiquitination of histones H2A and H2AX. This 
process of post-translational histone modifications is important in increasing chromatin 
accessibility to a number of regulatory factors.  Histone ubiquitination is relevant in 
nuclear process which govern gene silencing through activating or inhibiting 
transcription and maintaining genome stability, acting as a scaffold to organise DNA 
damage response (DDR) (109, 127, 128).  
 
 
DNA repair and signalling must occur to maintain cell viability and homeostasis. The 
most harmful type of DNA lesion is DNA double strand breaks (DSBs). A fault in DSB 
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repair can be associated with accelerated ageing, infertility, exhaustion of stem cell 
pools and impaired development of nervous and immune systems (126, 129, 130).  
 
RIDDLE (radiosensitivity, immunodeficiency, dysmorphic features, and learning 
difficulties) syndrome is a human immunodeficiency disorder associated with defective 
DSB repair. RNF168 E3 ligase initiates a DNA damage response (DDR) to DSBs by 
ubiquitination of histones H2A and H2AX. The targeting of histones is specifically 
monoubiquitination of K13-15 lysines (131, 132). RNF8 is the first E3 ligase recruited 
to the DSB damage site and initiates H2A or H2AX ubiquitination with K63-linked 
ubiquitin chains. RNF168 is also involved in catalysing RNF8–dependent histone 
ubiquitination. RNF168-dependent chromatin modifications coordinate the recruitment 
of 53BP1 and BRCA1 proteins, which are involved in DNA repair to DNA lesions. The 
mutated gene causing RIDDLE syndrome is RNF168. The inability of RNF168 to 
function normally, results in failure of 53BP1 and BRCA1 DNA repair factors to 
localise at the DNA damage site due to loss of histone ubiquitination (131, 133). 
 
RIDDLE syndrome presents with clinical features of increased radiosensitivity, mild 
motor control, immunodeficiency, learning difficulties and dysmorphic features. A 
illustration of 2 predicted products of mutated RNF168 alleles is shown (Figure 1.3.1) 
(124, 133).  
 
 
 
 
 
 
 
 
Figure 1.3.1: A depiction of the two predicted products of the mutated RNF168 
alleles derived from a RIDDLE syndrome patient A133fsx and Q44fsX (126). 
 
RNF168 has been found to play a role in the intrinsic antiviral defense against herpes 
simplex virus type 1 (HSV-1) through histone ubiquitination (121).  
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1.4.1.4 RNF168 and Herpes Simplex Virus Type 1 
Research has shown that when HeLa cells are infected with Herpes Simplex Type 1  
(HSV-1), a RING finger E3 ligase ICP0 modulates a cellular response to DNA damage. 
ICP0 is one of the first viral proteins that are expressed during HSV-1 infection. The 
deletion of ICP0 significantly impairs viral replication. The targets for ICP0 degradation 
are RNF8 and RNF168 cellular DNA damage ubiquitin ligases, which were responsible 
for ubiquitinating histones resulting in the anchoring repair factors at sites of damage 
(121, 122, 134). Chaurushiya et al suggest that ICP0 mimics a cellular phosphosite 
leading to degradation of RNF8(135).  Through targeting these ligases, ICP0 expression 
results in the loss of ubiquitinated forms of histones H2A and H2AX. This stops the 
recruitment mediator proteins Mdc1 and 53BP1, preventing the accumulation of repair 
factors at cellular damage sites. This pathway was identified as a key way in which 
HSV-1 overcame a host cell intrinsic antiviral defence. The basic outline of the pathway 
in which RNF168 contributes to intrinsic antiviral defence is shown below (Figure 
1.3.2) (121, 122, 134). 
 
                                                       
                                                        
                                                               RNF168  
 
 
 Modification Histone Proteins 
                                     
 
Recruitment of DNA repair factors at damage site 
 
 
                                                   Intrinsic Antiviral defence 
                                                
 
Figure 1.3.2: Basic pathway of how RNF168 contributes to antiviral defence based 
on research of HeLa cells infected with HSV-1.  
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A study found that when the HSV-1 wild type (WT) infected HeLa cells at a 
multiplicity of infection (MOI) 5:1 there was decrease in RNF168 expression 2 hours 
post-infection. To provide evidence to support the theory that HSV-1 infection led to 
the degradation of histones by ubiquitination, the same infected samples were probed 
for ubiquitinated H2A. This showed a decrease uH2A expression at 2 hours post 
infection. These finding were shown as a western blot (Figure 1.3.3) (121). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.3: ICP0 induces a decrease in RNF168 expression and loss of 
ubiquitinated H2A first seen at 2 hours post-infection (121). 
 
Both the changes seen with RNF168 and uH2A expression with WT did not occur for 
ICP0 null-virus (Figure 1.3.2). To confirm that ubiquitination was linked to the decrease 
in RNF168 expression seen, proteasome inhibitor was added, which rescued RNF168 
from degradation (121). 
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When applying this knowledge towards carrying out investigation into RNF168 it is 
clear that RSV and HSV-1 are two different viruses. The HSV-1 genomes enters the 
nucleus during replication whereas RSV replicates in the cytoplasm of cells (136, 137). 
Furthermore, RSV may not possess a protein equivalent to ICP0 that causes degradation 
of RNF168(121). This suggests that any mechanism by which RNF168 is affected by 
RSV infection would be different to HSV-1. Therefore, one of the main aims of this 
investigation will be to determine the mechanistic way in which RSV affects RNF168 
expression. At present there is very limited knowledge of the effect of RSV on RNF168 
expression in airways epithelial cells with evidence of any association gathered by our 
team. 
 
1.4.1.5 Evidence Supporting an Investigation into RNF168 and RSV 
Professor Ralph Tripp supplied a list of potential epithelial innate resistance genes. The 
graph below shows a list of these genes and the level of RSV N gene expression when 
these genes are knocked down by small interfering RNA (siRNA) (Apperley, Flanagan, 
McNamara and Tripp unpublished). Despite RSV N gene expression after RFFL, 
TRIM2 or RNF168 knockdown showing great variation, the level expression was 
considerably greater than the control. The graph below show the RSV N gene 
expression for all genes investigated (Figure 1.3.4) (Apperley, Flanagan, McNamara  
and Tripp unpublished). 
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Figure 1.3.4: RSV N gene expression for all genes knocked down by siRNA 
(RNF168 shown by arrow) (Apperley, Flanagan and McNamara unpublished). 
 
Another experiment involving the knockdown of RNF168, UBE2G2 and RFFL was 
carried out. A mean of 6 repeat experiments was calculated. There was little variation 
seen between experiments, making the data more reliable (Figure 1.3.5) (Apperley, 
Flanagan and McNamara unpublished). However, in comparison to the previous 
experiment (Figure 1.3.4), the levels of RSV N gene expression were not as high. 
Knockdown of RNF168 induced an increase in RSV N gene expression. However, the 
level of expression was less than 2 times greater than the level of the control (Figure 
1.3.4) (Apperley, Flanagan and McNamara unpublished).  
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Figure 1.3.5: Graph showing the percentage of RSV expression in relation to 
control for RFFL, UBE2G2 and RNF168 (Apperley, Flanagan, McNamara and 
Tripp unpublished). 
 
1.4.1.6 RNF168 Investigation Summary 
It was found previously that when the gene RNF168 was knockdown by siRNA, RSV N 
gene expression increased more than most of the other genes selected for knockdown 
(Apperley, Flanagan, McNamara and Tripp unpublished). The E3 ubiquitin ligase 
RNF168 has a role in antiviral defence when HeLa cells are infected with herpes 
simplex virus type 1 (HSV-1). RNF168 E3 ubiquitin ligase has been demonstrated to 
have a potential role for intrinsic antiviral defence to HSV-1 infection(121). It has been 
shown that RNF168 is responsible for modifying histone proteins by ubiquitination, 
which causes the recruitment of repair factors to double strand break sites (DSBs). A 
protein in HSV-1, ICP0, functions as an E3 ubiquitin ligase causing the degradation of 
RNF168(121). Given the role this protein plays in intrinsic antiviral defence, it is 
hypothesised that RSV affects the expression of RNF168 when overcoming the intrinsic 
antiviral defence of the target cell. 
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Therefore, due to this background knowledge, an investigation into RNF168 expression 
in RSV infected A549 cells were carried out. This was to determine the effect RSV had 
on the RNF168 and as a consequence how it could be implicated in the antiviral defence 
of a cell from RSV.  RSV time-course experiments were carried out to establish 
whether there was a relationship between duration of RSV infection and RNF168 
expression. Titration experiments were carried out to determine if there was a 
relationship between the multiplicity of infection (MOI) of RSV and RNF168 
expression. Experiments were also carried out with interferon beta stimulation of A549 
cells to see if interferon affected RNF168. This was because interferon is released from 
cells as part of the cell’s innate immune response and could have an effect on RNF168 
expression. Polyinosinic:polycytidylic acid (PolyI:C) is an immunostimulant which is 
known to interact with TLR3. It is considered to be a synthetic analogue of double-
stranded RNA like a virus and is recognised by TLR3. An investigation into the effects 
of polyI:C on RNF168 expression was carried out to see whether TLR3 had a 
mechanistic role in RNF168 expression (138).  
 
To provide supporting evidence that the experiment had been carried out effectively by 
infecting cells at the correct MOI and duration of infection, PCR of samples was carried 
out for RSV N gene expression. Interleukin-8 (IL-8) and interleukin-6 (IL-6) are 
proinflammatory cytokines produced by respiratory epithelial cells in response to RSV 
infection (48, 95).  
 
 
To provide additional evidence that the experiment had been carried out effectively by 
infecting cells at the correct MOI and duration of infection, Sandwich Enzyme enzyme-
linked immunosorbent assay (ELISA) for IL-8 and IL-6 were carried out on the 
supernatants taken from infected cells. To visibly establish the effect of RSV, polyI:C 
and interferon beta on RNF168, Western Blotting was used to measure RNF168 
expression.  
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1.4.2 CXCL5 Investigation  
1.4.2.1 Background  
Chemokines are grouped into 4 subfamilies, which are CXC, CC, CX3C and C on the 
basis of structural cysteine motif found near the amino acid terminus (139). CXCL5 
belong to the CXC chemokines family, which is predominantly implicated in the 
chemotaxis of inflammatory cells through the generation of local concentration 
gradients (140). Human CXCL5, is also referred to as epithelial cell-derived neutrophil-
activating peptide-78 (ENA-78), is involved in a variety of human inflammatory 
diseases (141). It has been shown that this chemokine is involved in neutrophil 
activation and recruitment. CXCL5 has been implicated in pulmonary disease, lung 
cancer, arthritis and other cancers. This CXC chemokine is also produced from adipose 
tissue when stimulated by cytokine TNF-alpha. This leads to the involvement of 
CXCL5 in inflammatory obesity-related diseases as shown in Figure 19 (139, 140).  
 
 
Figure 1.3.6: CXCL5 inflammatory obesity-related diseases (140). 
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1.4.2.2 Reasoning behind CXCL5 Investigation 
 
CXCL5 is a small cytokine belonging to the CXC chemokine family and has a role as a 
neutrophil chemoattractant. To understand the early event of RSV infection with 
regards to neutrophil activation and recruitment, proteomic analysis of a change in 
protein expression was carried out (Flanagan et al). A comparison was made between 
infected and control cells. This comparison was made by analysing samples using mass 
spectrometry coupled to nanoflow chromatography. Taqman PCR further measured 
expression of the neutrophil chemoattractant CXCL5 for samples infected at time points 
0, 2, 4, 6, 24 and 48 hours. The results suggest CXCL5 expression is transient peaking 
at 6 hours but only measured mRNA and not protein expression (Flanagan et al). If 
protein expression can be confirmed, it would suggest that CXCL5 might play a role in 
early neutrophil recruitment. To provide supporting evidence to the data obtained a 
CXCL5 enzyme-linked immunosorbent assay (ELISA) was carried out on supernatants 
collected from RSV infected A549 cells at 0, 2, 4, 6, 24, 48 hours.  
 
 
1.5 Aims 
The main aims of an investigation into RNF168 are: 
• To determine if RSV infection of A549 cells has an effect on RNF168 
expression  
• To gain a better understanding about how mechanistically this change in 
RNF168 expression occurs. 
 
The aims of an investigation into CXCL5 (additional topic) are: 
• To determine how CXCL5 levels are affected by RSV infection of A549 cells 
over various timepoints. 
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2. Materials and Methods 
2.1 Tissue Culture of A549 cells Splitting Cells into T75 flask and 24-well 
plates 
D.J Giard developed the A549 cell line in 1972 through the removal and culturing of 
cancerous lung tissue present in a 58 year-old male (142). A549 cells were grown in 
T75 flasks (Thermo Scientific) until confluent. The growth medium was Dulbecco 
Modified Eagle Medium (DMEM) (Sigma-Aldrich) with 10% Fetal Calf Serum (FCS) 
also known as fetal bovine serum (FBS) Gibco by Life Technologies) and gentamicin 
(Sigma-Aldrich, 50 mg/ml). Confluence was observed by microscope (Leica DFC420).  
The media was removed and cells were washed twice in 10ml of Phosphate Buffered 
Saline (PBS) (Sigma-Aldrich) to remove remaining dead cells. The PBS was removed 
and 3ml of trypsin (Sigma-Aldrich) added. The flask was incubated at 37 °C in 5% CO2 
for 1 minute before the trypsin was deactivated by adding 5ml of full media (DMEM 
with 10% FCS and gentamicin, 50mg/ml) to the flask. The contents of the flask were 
then transferred to a 10ml tube. The tube was spun in a centrifuge for 10 minutes at 
1500 revolutions per minute (rpm) (550G).   
 
The supernatant was discarded and pellet resuspended in 1ml of full media. A volume 
of approximately 200µl of this suspension was added to a T75 flask containing 15ml of 
media. This volume varied according to the number of cells required for the flask to 
reach confluence at a specific time. This was calculated by using a haemocytometer to 
do a cell count of the confluent flask before splitting. The remaining volume of 
suspended cells was used for seeding cells in a 24-well plate (Thermo Scientific) or 
discarded. Again the volume used depended on how fast the plate was required to reach 
confluence as well as the number of plates to be seeded.  
 
This was frequently 100µl in 10ml of full media (DMEM with 10% FCS and 
gentamicin). Cell counts were made using haemocytometer to estimate the number of 
cells, which should be seeded into each well. To each well of the 24-well plate, 1ml of 
full media (DMEM with 10% FCS and gentamicin) containing approximately 100,000 
cells was added. The cells were usually split so that wells would be fully confluent in 2 
days time. The 24-well plates and the newly split flask were left in an incubator at 37° C 
in 5% CO2 until required for use. Confluence was checked daily.  
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2.2 Harvesting RSV from T75 Flask 
It should be noted that RSV is most stable when within cells. Unbound virus degrades 
quickly so it was important to work quickly when thawing and freezing the virus 
containing cryovials.  
2.2.1 RSV Propagation  
30,000 Hep-2 cells/cm2 were seeded into a volume of 15ml full media (DMEM with 
10% FCS and gentamicin) in a T75cm2 flask and left to grow to approximately 50-70% 
confluence overnight at 37°C in 5% CO2. Media was then removed and the flask 
washed twice with PBS to remove cell debris and dead cells. A cryovial of rapidly 
thawed RSV was added to the flask along with 4ml of serum free media (DMEM with 
gentamicin but no FCS). For thawing, the cryovial was agitated in a water bath set to 
37°C. When the pellet is almost completely thawed the cryovial was taken to the hood 
where the contents were gently pipetted up and down to thaw remaining virus for quick 
use.  
 
The RSV was gently dispersed over the whole flask. The flask was left to rock gently 
for 2 hours in the incubator at 37°C in 5% CO2. After 2 hours 11ml of full media was 
added and the flask left for 24 hours. After 24 hours 11ml of the media in the flask was 
removed and replaced with serum free media making the percentage of FCS present in 
the flask 2%. The flask was assessed daily for cytopathic effect (dead cells floating in 
media). The flask was viewed under the microscope for the presence of syncytia (Figure 
2.1.1).  
 
 
 
 
 
 
 
 
 
Figure 2.1.1: Infected Hep-2 cells after 48 hours with syncytia present. 
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2.2.2 Harvesting RSV  
RSV was harvested at 48 hours. Most of the media was removed from the flask until 
4.5ml was remaining. Cells were harvested using a cell scraper and were placed in a 
10ml tube on ice and using a 2ml syringe with an orange needle (25 gauge) the cells 
were lysed by passing the cells through the syringe 10 times. The cells were spun down 
in a centrifuge at 1500 rpm (550G) for 5 minutes at 4°C.  
 
The pellet containing Hep2 cells debris was discarded and the supernatant retained. The 
supernatant (500µl per aliquot) was quickly transferred to pre-labelled cryovials and 
snap frozen in liquid nitrogen. The cryovials were transferred to the -80°C freezer. The 
batch number, date and location were noted in the stock folder. 
 
2.2.3 Plaque Assay for RSV  
The plaque forming units of RSV were measured using the following protocol: 
 
2.2.3.1 First Day  
Into a 96-well plate (flat-bottomed plate) 1x104 A549 cells/well were transferred with 
full media (DMEM with 10% FCS and gentamicin, 50mg/ml) and left overnight at 37°C 
in an incubator.  
 
2.2.3.2 Second Day 
In a separate plate, the virus stock was titrated out to be tested using dilutions starting at 
1/100. A minimum of 8 dilutions was done quickly with FCS free medium (DMEM and 
gentamicin 50mg/ml). The 96-well plate was removed from the incubator and the A549 
cells were washed with PBS. To the plate 50µl of the dilutions of virus stock per well 
was added. The plate was left for 2 hours at 37°C. To the plate 150µl of full media was 
added and left overnight at 37°C 
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2.2.3.3 Third Day  
The cells were washed with PBS (100µl/well) and fixed for 20 minutes (at room 
temperature) with 100% methanol containing 2% hydrogen peroxide (Sigma-Aldrich, 
Sigma). They were then washed with PBS again (100µl/well). Biotinylated anti-RSV 
antibody (Serotech Biotin, Goat) (1/200 dilution with PBS/1%BSA) was added, 100µl 
per well to the plate. The plate was left to incubate for 1 hour at room temperature 
before being washed with PBS/BSA twice. Afterwards 100µl of 1/500 dilution (in PBS) 
of extravidin peroxidase was added and left for 30 minutes at room temperature. The 
plate was washed with PBS/BSA twice and 50µl of 3 amino-ethylcarbazole substrate 
per well was added and left for 20 minutes to 24 hours. The 3 amino-ethylcarbazole 
(OPD (0-phenylenediamine) peroxidase substrate supplied by Sigma-Aldrich) was in 
tablet form and made up of the following: 
! 0.3ml of 3.3 mg/ml AEC in DMSO 
! 10µl hydrogen peroxide  
! 1.25ml, 24.3 mM citric acid  
! 2.6ml, 100 mM Na2HPO4 
! 1.15ml distilled water 
 
When plaques appeared and have acquired the desired coloration, PBS was added to the 
cells to stop reaction. The number of plaques was counted in the whole well. The 
dilutions of the virus were chosen so that there were 100-200 plaques per well and all 
replicates of that dilution were counted. From this an mean number of plaques were 
calculated. The plaque forming units are calculated by: Mean number of plaques x 
dilution x 20. An example of the plaque formation is shown (Figure 2.1.2). 
 
 
 
 
 
 
 
Figure 2.1.2: Image taken from microscope showing plaque formation (Brown 
areas). 
Plaque 
forming 
unit 
(brown) 
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2.3 Calculation of the appropriate level of Multiplicity of Infection (MOI) 
When setting up experiments it was important to know beforehand the specific 
multiplicity of infection (MOI) or range of multiplicity of infection to use. This was 
calculated by getting a ratio between the number of RSV particles and the number of 
cells in the well of a confluent 24-well plate. The number of cells in a confluent 24-well 
plate was calculated using a haemocytometer. The calculations from the plaque-forming 
assay gave an indication of the number of RSV particles. Based on this data, the volume 
of RSV to be used for an experiment was calculated.  
 
The reasoning behind  RSV MOI calculation is as follows: if there is 100,000 cells to be 
infected at a 1:1 MOI with the number of viral particles 1x106 per ml. For there to be 
one particle for one virus, the number of particles would have to be divided by 10. 
Therefore, 1x106  / 10 give 1 x105 virus particles for 1x105 cells giving a 1:1MOI. This 
means the volume to be added to cells must be divided by 10 i.e. per ml means 1ml 
divided by 10 to give 100µl of virus that must be added to cells.  
 
 
Range of MOIs used was from 0.025:1 to 1:1. An explanation of these MOIs is given in 
the table below.  
Table 2.1: Interpretation of RSV Multiplicity of Infection 
Multiplicity of Infection (MOI) Interpretation 
NI Control: A549 cells, which were not infected with 
RSV. 
0.025:1 For every 40 A549 cells there is one RSV virus 
particle 
0.25:1 For every 4 A549 cells there is one RSV virus 
particle 
0.5:1 For every 2 A549 cells there is one RSV virus 
particle 
1:1 For every 1 A549 cell there is one RSV virus 
particle 
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2.4 Cell count calculation of 24 wells plate  
The 1ml media from the well of the 24-well plate was removed and cells washed with 
500µl of PBS to remove any dead cells or cell debris. Trypsin (100µl) was added to the 
well of A549 cells to dislodge bound cells and the plate placed in the incubator for 1 
minute. The role of trypsin was to suspend the cells stuck down on the plate. The cells 
were then checked under a microscope to see how many cells were still stuck down. 
Full media (500µl) was added to the well. The cells were then scrapped from the well. 
The contents were then mixed up and down with a pipette. All of the 600µl in the well 
was transferred to a microcentrifuge tube and 10µl was taken for the haemocytometer.  
 
The number of cells was counted in each of the 4 quadrants of the haemocytometer. For 
example, if the values in the 4 quadrants were 24, 34, 40 and 37 then the mean is 33.75. 
The cell count calculation would be 33.75 x 104x0.6 (as the total volume was 600µl), 
which gives 202,500 cells per well.  
 
2.5 Infecting Cells  
When the cells in the 24-well plate had reached maximum confluence the media from 
wells was removed and replaced with 1ml FCS free media (DMEM that did not contain 
FCS only gentamicin, 50mg/ml). FCS free media was used because it encouraged the 
virus to attach to the cells. The RSV cryovial was taken from the freezer and left to 
thaw in the water bath until only a small piece of ice was visible in the cryovial. 
According to the multiplicity of infection (MOI) calculations that had been carried out 
before hand, a specific amount of RSV was added to selected wells quickly. The cells 
were then incubated at 37°C at 5% CO2. After 2 hours 1ml of full media was added to 
each well to give optimum conditions for the growth of A549 cells. The plate was 
placed back into the incubator at 37°C at 5% CO2 for a specific time period before 
harvesting.  
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There were 2 types of RSV infection experiments carried out. One was a MOI titration 
where cells underwent infection with different MOIs ranging from 0.025:1 to 1:1 either 
over 4 or 24 hours. All titration experiments had a control (NI) where a well of A549 
cells was not infected with RSV. The other experiment was a RSV time-course 
experiment where cells underwent infection with RSV over 0, 2, 4, 6, 24 and 48 hours. 
0 hours was where no RSV had been added and was used as a starting control. The 0 
hours samples were harvested immediately after all other samples had been infected 
with RSV. All time-course experiments had paired controls for each time point. When 
recording data controls were labeled as NI.  
 
2.6 Stimulating A549 Cells with Interferon-Beta, PolyI:C and Palivizumab.  
 
The range of concentrations of interferon-! (IFN-!) used was 1 to 100ng/ml.  The 
concentration of IFN-! used was 100µg/ml and the volume was 2µl in a 
microcentrifuge tube. The microcentrifuge tube was spun down for 10 seconds and 
placed on ice. The 2µl of IFN-! was taken and added to 198µl of full media in a new 
microcentrifuge tube to dilute the IFN-! to give a 1/100 dilution. The contents of this 
tube were used to stimulate A549 cells. The 24-well plate containing confluent A549 a 
cell was taken out of the incubator and the media removed from all wells to which IFN-
! was to be added.  
 
To stimulate A549 cells with 1ng/ml of IFN-! (Invivogen), 1µl of IFN-! (1/100 
dilution) was added to 999µl of media. If one sample was to be stimulated with 5ng/ml 
of IFN-!, 995µl of full media was added to the well with 5µl of the 1 in 100 dilution of 
IFN-!. If one sample was to be stimulated with 10ng/ml of IFN-!, 990µl of full media 
was added to the well with 10µl of the 1 in 100 dilution of IFN-!. If one sample was to 
be stimulated with 50ng/ml of IFN-!, 950µl of full media was added to the well with 
50µl of the 1 in 100 dilution of IFN-!. If one sample was to be stimulated with 
100ng/ml of IFN-!, 900µl of full media was added to the well with 100µl of the 1 in 
100 dilution of IFN-!. After stimulation the 24-well plate was placed back in the 
incubator at 37°C at 5% CO2 and left there until it was time to harvest the cells.  
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The media was removed from all wells where cells were to be stimulated with polyI:C. 
To each well 1ml of full media was added. Only a preliminary time course experiment 
was done, where 50ng/ml of polyI:C (Invivogen) was added to each well. The 24-well 
plate was placed back in the incubator at 37°C at 5% CO2 until it was time for each 
sample to be harvested.   
 
To show that changes in RNF168 expression were affected by RSV and not another 
factor, cells were infected with RSV MOI 1:1, which had been mixed with 5µl 
palivizumab (Synagis, MedImmune). The normal infection protocol and harvesting this 
sample for real-time PCR and Western blotting was carried out (See Sections 2.5 and 
2.7). 
 
2.7 Harvesting Cells for Enzyme-Linked Immunosorbent Assay (ELISA) 
and Western Blot 
 
Culture supernatants were removed and transferred to a labelled microcentrifuge tube. 
The tubes were stored in a -20°C freezer until they were required for analysis by the 
Enzyme-Linked Immunosorbent Assay (ELISA). After the supernatant had been taken, 
the cells were harvested for the Western Blot.  
 
Firstly, 1ml of Phosphate Buffered Saline (PBS) was added to the wells and cells were 
scraped using a cell scraper from the bottom of the well so that they were suspended in 
the PBS. This suspension was transferred to a labelled 10ml tube. The well was then 
washed with 1ml of PBS again and the contents transferred to the same 10ml tube. This 
was done so that any protein left in the well would not be lost. This process was 
repeated for all samples. All of the 10 ml tubes containing each sample were then spun 
in a centrifuge for 10 minutes at 1500 rpm (550G).    
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Afterwards, the supernatant was discarded and pellets resuspended in 500µl of PBS and 
transferred to a labelled microcentrifuge tube. Tubes were placed in a mini-centrifuge 
and spun at maximum speed for 3 minutes at 13.3 x 104 rpm.  The supernatant was then 
removed from the microcentrifuge tubes to leave dry pellets, which were placed in the -
20°C freezer. The pellets were then used to run a western blot the day after or were put 
in Sodium Dodecyl Sulfate (SDS) (with protease inhibitor and dithiothreitol) and stored 
at -30°C until required for further use.  
 
 
 
2.8 Western Blotting, ELISA and Real-time PCR 
2.8.1 Background and Theory of Western Blotting (primary source: Advansta 
Protein Analysis: Electrophoresis, Blotting and Immunodetection) 
Western blotting, an analytical technique used for the study of proteins allows detection 
of a single protein among a mixture of proteins from a biological sample, allowing an 
estimation of molecular weight and relative amount. This protein mixture is separated 
using a polyacrylamide gel then electrically transferred to a PVDF membrane (143).  
 
The membrane is a replica of protein composition and pattern making it possible to 
detect target proteins due to antibody-antigen interaction. The specificity of this 
technique is attributed to the antibody, which recognises and binds to an epitope unique 
to the protein of interest. This technique consists of sample preparation, electrophoresis, 
separation of proteins, transfer of proteins, membrane staining and developing (143).  
 
 
 
 
 
 
 
 
A brief overview of the process of Western Blotting with diagrammatic representation 
is shown below (Figures 2.3, 2.4 ad 2.5) (143):  
!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%$!"()%&'(*+%,%$!!!!!!!!!!!!!!!!!!!!-.'/0!/$!1'/02!3(%0&'!!
! 9<!
 
1) Sample preparation: Proteins from A549 cells are harvested as explained in the 
previous section. To the microcentrifuge tube containing the protein pellet, 
Sodium Dodecyl Sulphate (SDS) is added. This causes the proteins to be coated 
with a negative charge so that they will separate when run on the gel based on 
size. Bromophenol blue a blue dye, is added to samples to aid in loading. The 
dye will migrate ahead of proteins on the gel so that the progress of the gel can 
be monitored. Protease inhibitor is added to prevent the degradation of the 
protein of interest. Dithiothreitol (DTT) is added to the samples as a reducing 
agent. DTT prevents the oxidation of cysteines and will complete protein 
unfolding by breaking disulphide bonds between cysteine residues.  
 
2) Polyacrylamide electrophoresis: The polyacrylamide gel is placed in an 
electrophoresis tank, filled with buffer. Samples are loaded with a tip into the 
wells of the polyacrylamide gel (Figure 2.3). The electrophoresis supply is 
attached to a power supply, which provides the voltage. When the power supply 
is turned on, the negatively charged proteins migrate away from the anode.    
The protein is separated according to size by electrophoresis.  
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Figure 2.1.3: Sample loading and setting up of the polyacrylamide gel for 
electrophoresis(143).  
 
 
3) Electrophoretic transfer to membrane support: The proteins are transferred 
electrophoretically to a membrane where they are immobilised. The membrane 
is a solid support, which binds and immobilises the protein allowing for 
detection by antibody hybridisation. Systems for transfer use an electric current 
to drive the negative charged protein towards the positive electrode. The 
membrane used for transfer is polyvinylidene difluoride (PVDF). Membranes 
can also be made of nitrocellulose. The advantages of PVDF membranes are that 
they offer mechanical strength and a higher bonding strength than nitrocellulose.  
 
4) Blocking and Antibody hybridisation:  The membrane is blocked to prevent 
non-specific binding of the antibodies (Figure 2.1.3). The protein-based 
blocking agent used is non-fat dry milk. This is preferred to BSA because it is 
cost effective. The blocking agent is diluted in Tris-buffered Saline (TBS) with 
Tween 20 detergent added. The membrane was then incubated with primary 
antibody directed against specific epitope present on target protein.  
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5) Information and background about antibodies: The antibodies used in this 
investigation were monoclonal antibodies. The production of monoclonal 
antibodies involves synthesising cells, which are isolated from the spleen of an 
immunised animal and fused with myeloma cells. This forms hybridomas, which 
secrete antibodies into their culture media. These antibodies are tested for their 
affinity to antigen. Hybridomas having the most stable production of antibodies 
are selected and grown in culture indefinitely. After several washes to remove 
unbound antibody, the secondary antibody is added and binds to the primary 
antibody, providing a means of detection.  
 
The primary antibody is diluted in the blocking agent and applied so that it 
covers the entire membrane (Figure 2.1.4). The antibody manufacturer may 
recommend the starting dilution but the concentration of antibody required for 
the best image must be determined empirically. Factors that were taken into 
account when selecting the antibody concentration were, abundance of target 
protein in the sample, the affinity of the antibody for the protein of interest and 
the sensitivity of the detection system used.  
 
The primary antibody is usually kept on overnight at 4°C. The time that the 
primary antibody should be left on is recommended in the manufacturer guide. 
After incubation the primary antibody is washed away using wash buffer. The 
secondary antibody is added to the membrane (Figure 2.1.4). Selection of the 
secondary antibody depends on the species in which the primary antibody was 
made. For example if the primary antibody was made in rabbit, then the 
secondary antibody will be anti-rabbit (a secondary raised in a species other than 
rabbit).  
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Figure 2.1.4: Blocking membrane. Process of adding primary and secondary 
antibodies (143). 
 
 
6) Detection: Detection of the protein can be achieved through 
chemiluminescence, fluorescence and colorimetric techniques. In this 
investigation chemiluminescence was used to detect the protein of interest.  
Chemiluminescence methods commonly use horseradish peroxidase enzyme 
(HRP)-conjugated secondary antibodies (Figure 2.1.5). The reaction between the 
horseradish peroxidase enzyme and substrate produces light, which can be 
detected by exposing the blot to an x-ray film (Figure 2.15). The advantages of 
chemiluminescence are that the membrane can be stripped and reprobed, 
multiple exposures can be done with x-ray films, the results can be easily 
documented and this technique is highly sensitive.  
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Figure 2.1.5: Diagrammatic representation of the binding of primary and 
secondary antibody to membrane (143).  
 
2.8.2Western Blotting Protocol  
This is more specific detail about how the technique of Western Blotting was applied in 
this project.  
 
2.8.2.1 Sample Preparation  
Samples were taken from the -30 degrees freezer and thawed on ice. The pellet was 
dissolved at 100°C for 3 minutes in denaturing and reducing buffer consisting of 
anionic denaturing detergent Sodium Dodecyl Sulphate (SDS), 10% Dithiothreitol 
(Sigma-Aldrich, Sigma) and a 1 in a 100 dilution of Protease Inhibitor (PI) (Thermo 
Scientific). The tubes were then placed on ice ready to load onto the gel. Of each 
sample, 5µl was loaded into each well of the Bio-Rad Miniprotein precast gel (12% 
Tris/ glycine buffer), which was run in the Bio-Rad Western Blot System 
(electrophoresis tank) using running buffer at 140 volts. 
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To make up running buffer the following was added and mixed in a 1 litre bottle:  
• 3.03 grams Tris Base (Fisher Chemical) 
• 14.4 grams Glycine (Fisher Chemical) 
• 1 gram SDS (Bio-Rad Electrophoresis) 
• 1 litre of double-distilled water  
 
Precision Plus Protein Standards All Blue (also known as ladder) (Bio-Rad) was loaded 
into the first well to enable the size of the detected bands to be measured. The ladder 
gave an indication of where precisely to cut the gel to select the proteins of interest for 
analysis. The ladder showing where the proteins of interest are located has been shown 
(Figure 2.1.6). 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Figure 2.1.6: Precision Plus Protein All Blue Standards.The arrows indicate the 
rough location of proteins of interest.  
 
 
 
?@A49;!!!
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The gel was run for 1 hour. Afterwards the gel was removed from the electrophoresis 
tank and the plastic cassette enclosing the gel removed. Using the relative positions of 
the protein ladder, the gel was cut to select an area where the proteins (RNF168 and !-
actin) of interest were located.  
  
2.8.2.2 Protein Transfer  
The gel was placed on top of a PVDF membrane (Transblot-Turbo Transfer Pack 
0.2µM PVDF, Bio-Rad USA) and sandwiched between papers pre-wetted with transfer 
buffer. An electric field (positive to negative) (Trans-Blot® Turbo™ Transfer System, 
Bio-Rad) at mixed molecular weight setting was applied for 7 minutes to the transfer 
the proteins from gel to the membrane. The membrane containing the gel samples was 
then cut out and left to block in 5% skimmed milk solution (1g Marvel milk in 20ml 
1xTris Buffer Saline (Sigma-Aldrich, Sigma) with 0.5% Tween (1xTBST)) for 30 
minutes. Blocking the membrane prevents non-specific binding of primary and 
secondary antibodies to the membrane.  
 
2.8.2.3 Immunostaining 
While the membrane was left to block, the primary antibody was diluted in 5% 
skimmed milk solution (1g of milk in 20ml 1xTBST) as a 1/1000 dilution. After 
blocking, the milk was removed and the primary antibody RNF168 (Abcam) was added 
to the membrane and incubated overnight at 4°C with agitation. This is an example 
given of probing the membrane for RNF168.  
 
The next day the membrane was washed in 1x TBST in 5 separate washes lasting 1, 3, 
10, 5 and 5 minutes. The secondary antibody, anti-mouse (Mouse) was added as a 
1/1000 dilution and left on the rocker for 1 hour at room temperature with agitation. The 
washes with 1x TBST were repeated again.  
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2.8.2.4 Developing Blot 
ECL Prime Western Blotting Detection Reagent (GE Healthcare life Sciences, 
Amersham) was made up using equal volumes of solution A and solution B. This 
volume was frequently 500µl of each solution. After washes, the membrane was placed 
on cling film and covered with ECL for 5 minutes. After 5 minutes the membrane was 
wrapped up in another piece of cling film and transferred to a cassette. 
 
In the dark room the ECL High Performance chemiluminescence film (Amersham 
Hyperfilm) was placed down over the membrane for 10 seconds. The film was then 
developed for 1 minute in 400 ml of developer G153 (Agfa Healthcare Inv, Belgium), 
rinsed in 400ml distilled water, then 1 minute in 400ml of Fixer G354 (Agfa Healthcare 
Inv, Belgium) and rinsed in 400ml water again.  
 
The instructions for making developer and fixer are: 
• Developer (400ml): 50ml solution B (G153, part B, Agfa Healthcare Inv, 
Belgium) + 150ml solution A (G153, part A, Agfa Healthcare Inv, Belgium) + 
200ml water 
• Fixer (400ml): 100ml fixer (G354 Agfa Healthcare Inv, Belgium) + 300ml water 
 
 
The film was then hung to dry. Afterwards the film was lined up with the membrane, 
which was still taped to the cassette. This was to see whether the bands that had 
developed were in fact the protein of interest by measuring the number of Kilodaltons 
of protein against the ladder and comparing this estimate with number of Kilodaltons 
that the protein is stated to be according to the manufacturer.  
 
2.8.2.5 Probing for Actin 
To check that protein had been loaded evenly and in order to get a ratio of the level of 
expression of the protein of interest, beta-actin (!-actin) (Mouse) was probed. This 
involved taking the membrane out of the cassette and leaving it to the block in 5% 
skimmed milk solution for 30 minutes. The primary antibody !-actin was diluted in 5% 
skimmed milk solution as 1/1000 dilution and added to the membrane. The milk was 
removed and the primary !-actin antibody added to the membrane.  
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The membrane was then left for 1 hour on a rocker. The primary antibody was removed 
and the membrane washed with 1x TBST in 5 separate washes for 1, 3, 10, 5 and 5 
minutes. The secondary antibody, anti-mouse (Goat) was diluted in 5% skimmed milk 
solution as a 1/1000 dilution, was added. The membrane was agitated for 1 hour at room 
temperature. The antibody was removed and washed again in 1xTBST. The steps for 
developing the blot were repeated.  
 
Tables 2.2 and 2.3 provide the details for the antibodies used throughout this 
investigation.   
 
 
Table 2.2: Conditions Required for Each Antibody 
 
Antibody Duration and Conditions of Antibody left on 
Membrane 
Anti-RNF168 Overnight at 4°C with agitation 
!-Actin 1 hour at room temperature with agitation 
Anti-Mouse 1 hour at room temperature with agitation 
 
 
Table 2.3: Primary and Secondary Antibodies 
 
 
 
Primary 
Antibody 
Manufacturer 
and Catalogue 
Number 
Kilodaltons 
(kDa) 
Secondary 
Antibody 
Manufacturer 
and Catalogue 
Number 
Anti-RNF168 
(Mouse) 
ABCAM 
Catalogue 
number: 
ab58063 
65 Anti-Mouse 
IgG HRP 
(Goat) 
R&D Systems 
Catalogue: 
HAF007 
!-Actin 
(Mouse) 
ABCAM 
Catalogue 
Number: 
ab8226 
42 Anti-Mouse 
IgG HRP 
(Goat) 
R&D Systems 
Catalogue: 
HAF007 
 
 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%$!"()%&'(*+%,%$!!!!!!!!!!!!!!!!!!!!-.'/0!/$!1'/02!3(%0&'!!
! :;!
2.8.2.6 Measuring RNF168 Expression 
Western blotting is an analytic technique, providing one of the most effective visual 
representations of protein expression. This technique was used to investigate how the 
expression of RNF168 was affected by different stimuli. The !-actin expression for the 
same sample was measured as a loading control to determine the amount of protein 
loaded for each sample. As a result, the level of RNF168 expression relative to !-actin 
could be measured. This made the densitometry values acquired more reliable as it 
would show the true level of RNF168 in each sample accounting for uneven protein 
loading. Densitometry of the RNF168 and !-actin were carried out using ImageJ 
software. The densitometry values for the protein of interest were divided by the 
densitometry values for !-actin to give the level of expression relative to !-actin.  
 
Densitometry analysis is measuring the intensity of band of a protein. The darker the 
band the greater the expression of the protein. An example of this is shown below with 
RNF168 (Figure 3.2). 
 
 
 
RNF168  
 
Beta-actin 
 
Densitometry value for RNF168 = 603 
Densitometry value for !-actin = 9473 
Level of RNF168 expression relative to !-actin = 603/9473=0.06. 
 
Figure 2.1.7: Calculating the level of RNF168 expression relative to !-actin. The 
density of both bands for RNF168 and !-actin were measured and the level of RNF168 
expression relative to !-actin calculated. The values were plotted in a graph where the 
level of RNF168 expression relative to !-actin was the y-axis and the stimuli (specific 
to concentration/MOI) were plotted on x-axis (where NI= control). 
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2.8.3 Enzyme-Linked Immunosorbent Assay (ELISA) Background and 
Protocol 
2.8.3.1 ELISA Background  
The purpose of an enzyme linked immunosorbent assay (ELISA) is to quantify how 
much protein there is (144). Before the development of ELISA, radioimmunoassays 
were used. This involved using radioactive labelled antibodies and antigens. However, 
due to health threats of this technique, safer options were required. As a result, Swedish 
scientists Eva Engvall and Peter Perlmann primarily developed the ELISA technique in 
1971(144, 145).  
 
An ELISA is carried out using a 96-well plate because they give high throughput 
results. The type of ELISA being used here is a Sandwich ELISA where a sample 
antigen is detected and quantified between two layers of antibodies (capture and 
detection). The advantage of a Sandwich ELISA is that the sample does not need to be 
purified. Furthermore, the ELISA is very sensitive and potentially can be 2-5 times 
more sensitive than an indirect and direct ELISA. Sandwich enzyme-linked 
immunosorbent assays use antibodies and colour change to identify a substance as well 
as how much of that substance there is. The ELISAs were performed using the materials 
provided by the Duoset ELISA Development kit (R&D Systems) to measure natural and 
recombinant interleukin-8 (IL-8), interleukin-6 (IL-6) and CXCL5 (also known as 
ENA-78) (144, 146).   
 
When cells undergo infection they proinflammatory cytokines as a response. These 
proinflammatory cytokines include interluekin-8 (IL-8) and interleukin-6 (IL-6). A549 
cells produce increasing levels of IL-8 and IL-6 in response to RSV infection (147, 
148). If the MOI of infection increases then there will be more virus particles to 
stimulate more cells to release these cytokines. Thus, to provide supporting evidence 
that A549 cells undergo infection by RSV and that the RSV MOI titration experiments 
have been carried out accurately, the supernatant from each sample was taken for IL-8 
and IL-6 Sandwich ELISAs (148) 
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Taqman PCR measured expression of the neutrophil chemoattractant CXCL5 for 
samples RSV infected at time points 0, 2, 4, 6, 24 and 48 hours. The results suggest 
CXCL5 expression is transient peaking at 6 hours. To provide supporting evidence to 
the data obtained CXCL5 Sandwich ELISA was carried out on supernatants collected 
from RSV infected A549 cells at 0, 2, 4, 6, 24, 48 hours with controls at each time 
point. 
2.8.3.2 Interleukin-8 (IL-8), Materials Required for ELISA by R&D Systems (149) 
 
The following materials were used and brought to room temperature before use (149): 
 
• Capture antibody (1 vial): 720µg/ml of mouse anti-human IL-8/CXCL5 when 
reconstituted with 1.0ml of PBS. After reconstitution, it was aliquoted and 
stored at -70° C in a manual defrost freezer for up to 6 months. The capture 
antibody was then diluted to a working concentration of 4.0µg/ml in PBS, 
without carrier protein.  
• Detection antibody (1 vial): 3.6µg/ml of biotinylated goat anti-human IL-
8/CXCL5 when reconstituted with 1.0ml of Reagent Diluent (see Solutions 
Required section). After reconstitution, the detection antibody was stored at -
70°C in a manual defrost freezer for up to 6 months. The detection antibody was 
diluted to a working concentration of 20ng/ml in Reagent Diluent. 
• Standard (3 vials): 100ng/ml of recombinant human IL-8/CXCL5 when 
reconstituted with 0.5ml of distilled water. The standard was allowed to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions. The 
reconstituted standard was aliquoted and stored at -70°C for up to 6 months. A 
seven-point standard curve using 2-fold serial dilutions in Reagent Diluent, and 
a high standard of 2000 pg/ml was recommended. 
• Streptavidin- horseradish peroxidase (HRP) (1 vial): 1.0ml of Streptavidin 
conjugated to horseradish-peroxidase. Streptavidin-HRP was stored at 2-8°C for 
up to 6 months after initial use. It was diluted to a 1/200 working concentration 
using Reagent Diluent.  
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2.8.3.3Interleukin-6 (IL-6) Materials Required for ELISA provided by R&D Systems 
(150) 
 
The following materials were used and brought to room temperature before use:  
 
• Capture Antibody (1 vial) - 360 mg/ml of mouse anti-human IL-6 when 
reconstituted with 1.0 ml of PBS. After reconstitution, capture antibody was 
stored at -70° C in a manual defrost freezer for up to 6 months. Capture antibody 
was diluted to a working concentration of 2.0 mg/ml in PBS4, without carrier 
protein. 
• Detection Antibody (1 vial) - 9 mg/ml of biotinylated goat anti-human IL-6 when 
reconstituted with 1.0 ml of Reagent Diluent (see Solutions Required section). 
After reconstitution, detection antibody was aliquoted and store at -20° C to -
70°C in a manual defrost freezer for up to 6 months. Detection antibody was 
dilute to a working concentration of 50ng/ml in Reagent Diluent. 
• Standard (1 vial) - 120ng/ml of recombinant human IL-6 when reconstituted with 
0.5ml of distilled water. Allow the standard to sit for a minimum of 15 minutes 
with gentle agitation prior to making dilutions. The reconstituted standard was 
aliquoted and stored at -70° C for up to 6 months. A seven-point standard curve 
using 2-fold serial dilutions in Reagent Diluent, and a high standard of 600pg/ml 
was recommended. 
• Streptavidin-HRP (1 vial) - 1.0mL of streptavidin conjugated to horseradish-
peroxidase. Streptavidin-HRP was stored at 2-8° C for up to 6 months after 
initial use. Streptavidin was diluted to the working concentration specified on 
the vial label (1 in 200 dilution) using Reagent Diluent.  
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2.8.3.4 CXCL5 Materials Required for ELISA provided by R&D Systems (151) 
 
The following materials were used and brought to room temperature before use:  
 
• Capture Antibody- 360 mg/ml of mouse anti-human ENA-78 when reconstituted 
with 1.0 ml of PBS. After reconstitution, capture antibody was aliquoted and 
stored at -70° C in a manual defrost freezer for up to 6 months. Capture antibody 
was diluted to a working concentration of 2.0 mg/ml in PBS, without carrier 
protein. 
• Detection Antibody- 18 mg/ml of biotinylated goat anti-human ENA-78 when 
reconstituted with 1.0 ml of Reagent Diluent (see Solutions Required section). 
After reconstitution, detection antibody was stored at -70° C in a manual defrost 
freezer for up to 6 months. Detection antibody was diluted to a working 
concentration of 100ng/ml in Reagent Diluent. 
• Standard- Each vial contains 90 ng/ml of recombinant human ENA-78 when 
reconstituted with 0.5 ml of Reagent Diluent (see Solutions Required section). 
The standard was allowed to sit for a minimum of 15 minutes with gentle 
agitation prior to making dilutions. The reconstituted standard was aliquoted and 
stored at -70° C for up to 2 months. A seven-point standard curve using 2-fold 
serial dilutions in Reagent Diluent, and a high standard of 1000 pg/ml is 
recommended. 
• Streptavidin-HRP- 1.0ml of streptavidin conjugated to horseradish-peroxidase. 
Streptavidin-HRP was stored at 2-8°C for up to 6 months after initial use. It was 
diluted to the working concentration specified on the vial label (1 in 200 
dilution) using Reagent Diluent.  
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2.8.3.5 Solutions Required for IL-8, IL-6 and CXCL5 ELISA 
 
The Bovine Serum Albumin (98% (BSA) used to make block buffer and Reagent 
Diluent must be good quality as this is critical towards the quality of results obtained. 
This is so that impurities such as proteases, binding proteins, soluble receptors or other 
substances, which interfere with the detection of certain analytes, are reduced.  
 
The solutions required for ELISA include: 
• Phosphate buffered saline (PBS)- 137 mM NaCl, 2.7 mM KCl, 8.1 mM 
Na2HPO4, 1.5 mM KH2PO4, pH 7.2-7.4, 0.2 µm filtered. 
• Wash buffer- 0.05% Tween 20 in PBS, pH 7.2-7.4. (R&D Systems Cat # 
WA126) 
• Block buffer- For CXCL5 and IL-8: 1% BSA in PBS with 0.05% NaN3. For 
IL-6: 1% BSA in PBS, pH 7.2-7.4 
• Reagent diluents- For IL-8: 1% BSA, 0.05% Tween 20 in Tris-buffered Saline 
(20 mM Trizma base, 150 mM NaCl), pH 7.2-7.4, 0.2 µm filtered. For CXCL5 
and IL-6: 1% BSA in PBS, pH 7.2-7.4, 0.2 mm filtered.  
• Substrate solution- 1:1 mixture of Colour Reagent A (H2O2) and Colour 
Reagent B (Tetramethylbenzidine).(R&D Systems Catalog # DY999). 
• Stop solution- 2 NH2SO4 (R&D Systems Catalog #DY994). 
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2.8.3.6 Interleukin-8, Interleukin-6 and CXCL5 (ENA-78) Plate Preparation(149-
151) 
 
Plate Preparation 
1. The Capture Antibody was diluted to the working concentration in PBS  (Sigma-
Aldrich, Sigma pH 7.4) without a carrier protein. The 96-well plate (Thermo 
Scientific) was then immediately coated with 100µl per well of diluted Capture 
Antibody. The plate was sealed and incubated overnight at room temperature. 
For all steps in this protocol fresh reagent reservoir container and pipette tips 
were used.  
2. Each well was aspirated and washed with Wash Buffer. The washes were 
repeated 2 further times for a total of 3 washes. Washes were carried out with 
400µl per well of Wash Buffer using an autowasher (Bio-tek). For good 
performance complete removal of liquid at each step is essential.  After the final 
wash, the plate was inverted and blotted against paper towels to remove any 
remaining Wash Buffer.  
3. Plates were blocked by adding 300µl of Block Buffer to each well. The plates 
were then incubated at room temperature for a minimum of 1 hour.  
4. Washes were repeated as in step 2. The plate was now ready for sample 
addition.  
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2.8.3.7 Assay Procedure (149-151) 
1. To each well a 1 in 10 dilution of sample in Reagent Diluent (total volume 
100µl) was added. Dilutions were judged empirically. Samples were diluted in 
reagent diluent so that values could be read and were within the standard curve 
as the cells produce high levels of IL-8. The levels of IL-6 produced tend to be 
less so the sample was added directly to the ELISA plate without dilution. For 
CXCL5 the dilution was 1 in 50. The plate was covered with an adhesive strip 
and incubated at 1 hour at 37°C with agitation. All samples were done in 
duplicate and a plate layout recorded.  
2. Washes were repeated as in step 2 of the Plate Preparation.  
3. Detection Antibody (100µl) diluted in Reagent Diluent was added to each well. 
The plate was covered with an adhesive strip and incubated for 1 hour at 37°C 
with agitation. 
4. Washes were repeated as in step 2 of the Plate Preparation.  
5. A working dilution of Streptavidin-HRP (100µl) was added to each well. The 
plate was covered and incubated at room temperature for 20 minutes. Avoid 
placing the plate in direct light.  
6. Washes were repeated as in step 2 of the Plate Preparation. 
7. Substrate solution (Ultra TMS ELISA, Thermo Scientific) (100µl) was added to 
each well. The plate was incubated for 20 minutes at room temperature in a 
drawer so that it was not in contact with direct light.  
8. Stop solution (BDH AmalaR)(50µl) was added to each well. The plate was 
tapped to ensure thorough mixing. The optical density of each well was 
determined using a microplate reader (Bio-tek) set to 450nm. 
 
 
 
 
The ELISA software, KC Junior was used to record the concentration level of IL-6, IL-
8 and CXCL5. The duplicate values for each sample were meand and plotted as a graph. 
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2.9 RNA Extraction, Reverse Transcription and Real-time PCR 
In order for RSV infected samples of A549 cells to be run for real- time PCR, samples 
must first undergo RNA extraction (isolation) and reverse transcription. The processes 
leading to real-time PCR are shown in the figure below (Figure 2.1.8). 
 
Figure 2.1.8: Summary of steps that lead to PCR (152). 
 
2.9.1 RNA Extraction Protocol  
The RNA from RSV infected A549 cells in a 24-well plate were extracted using the 
Qiagen QIA shredder and RNeasy mini kit. This protocol was modified from Qiagen 
RNA mini kit (153, 154). 
For a 24-well plate containing infected A549 cells (153, 154) : 
1. The supernatant was removed from wells.  
2. 350µl buffer RLT (guanidine-thiocyanate–containing buffer) (Qiagen)/2-
mercaptoethanol (!-ME) (Sigma-Aldrich, Sigma) (10µl !-ME to every 1ml RLT 
buffer) per well was added to a microcentrifuge tube. (At this point the 
microcentrifuge tube can be placed in a -70°C fridge and further steps carried 
out at a later time). This was to remove RNA from the cells. The purpose of 
RLT buffer was to lyse cells before RNA isolation from cells. The addition of 
buffer RLT also causes the inactivation of ribonuclease (RNase), ensuring 
purification of intact RNA. 2-mercaptoethanol is used to eliminate ribonuclease 
released during cell lysis.  Ribonuclease is made up of several disulfide bonds, 
which make the enzyme very stable, and it is these bonds which 2-
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mercaptoethanol reduce and denature irreversibly. This is so that ribonuclease 
does not digest the RNA during the extraction procedure.  
3. All of the 350µl was added to the QIA shredder spin column (Qiagen). The spin 
column was placed in a 2ml collection tube and spun for 2 minutes at full speed 
(13.3x 104 rpm or 15,821G). The QIA shredder is a unique biopolymer 
shredding system in microcentrifuge spin-column format. It homogenises cell or 
tissue lysate to reduce viscosity.  Homogenisation shears the high molecular-
weight cellular components to create a homogenous lysate. The QIA shredder is 
chemically inert and does not bind nucleic acids.  
4. The QIA shredder was then discarded. To the sample in the 2ml collecting tube, 
350µl of 70% ethanol was added and mixed well by pipetting.  
5. All of the contents of the 2 ml collection tube (700µl) were added to the RNeasy 
spin column (Qiagen) placed in a new 2ml collection tube. This makes up part 
of the RNeasy procedure where RNA is purified. This technology combines the 
microspin technology with the selective binding properties of a silica –based 
membrane. The specialised high salt buffer systems enables up to 100%g of 
RNA longer than 200 bases to bind to the RNeasy silica membrane. The 
addition of ethanol was to provide the appropriate binding conditions. When the 
sample is added to the RNeasy spin column, total RNA binds to the membrane 
and contaminants are washed away.    
6. The contents were then spun at full speed for 15 seconds in the mini-centrifuge 
at full speed. The flow through was then discarded.  
7. Buffer RW1 (700µl)(Qiagen) was then added to the column and the contents 
spun for 15 seconds at full speed. The flow through was discarded.  Buffer RW1 
is added to wash the membrane bound RNA.  
8. To the column 500µl of RPE (Qiagen) was added to the column. The column 
was spun for 15 seconds at full speed. The flow through was discarded.  
9. Another 500µl of RPE was added to the column. The column was spun for 2 
minutes at full speed. Buffer RPE is a concentrated wash buffer for washing 
membrane bound RNA.  
10. The RNeasy spin column was carefully removed from the collection tube, 
ensuring that it does not contact the flow through. The spin column was placed 
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in a new 2ml collection tube (the old collection tube containing flow through 
was discarded). The contents were spun for 1 minute at full speed. 
11. The RNeasy spin column was placed in new 1.5ml microcentrifuge tube.  
12. RNAse free water (40µl) (Fisher) was added directly to the membrane and left 
for 2 minutes.  The contents were spun at full speed to elute RNA.  
13. The RNA was placed immediately on ice and transferred to the -70°C freezer or 
measured for the quality of RNA using nanometry. When it was time for reverse 
transcription the samples were placed on ice. A summary diagram of the process 
of RNA extraction has been provided (Figure 2.1.9) 
 
2.9.2 Quantification of RNA Purification  
 
Nucleic acid is quantified using a spectrophotometer. Analysis of RNA purity is by the 
NanoDrop ND-1000.RNA has an absorption maximum of at 260 nanometres (nm). The 
ratio of absorption at 260 and 280nm is used to assess RNA purity of RNA preparation. 
Pure RNA has a ratio of absorption between 1.8 and 2.0. An A260 reading of 1.0 is 
equivalent to 40µg/ml of RNA. The optical density at 260 nm is used to determine the 
RNA concentration in a solution (155). 
 
After RNA had been obtained, the quality of the RNA was measured by nanodrop by 
carrying out the following(155): 
1. The computer and nanodrop was turned on. 
2. The nanodrop software was opened and nucleic acid selected. 
3. When prompted 1µl RNAse free water (Fisher) and OK button selected.  
4. The sample type was changed to RNA 40  
5. 1µl RNAse free water was added and the blank button selected.  
6. The water was wiped from the nanometer and with tissue paper 
7. 1µl of the sample was added to the nanometer and measure button selected.  
8. Afterward 1µl RNAse free water was added and the lid closed. 
9. Wipe between samples.  
10. When all of the samples have been measured select ‘show report’ then ‘reports-
save reports’ and finally select ‘export table.’ 
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Values taken from a set of samples measured by the nanometer are shown in the 
table below (Table 2.3). This set of samples was from an RSV time-course 
experiment. 
 
 
 
Table 2.3: Nanometry Values  
 
Duration of RSV Infection Ratio of Absorption 
0 Hours 1.94 
2 Hours  2.13 
4 Hours 2.13 
6 Hours 2.12 
24 Hours 2.15 
48 Hours 2.15 
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Figure 2.1.9: RNA extraction basic outline. The method applied here is the ‘RNeasy 
Mini Procedure (154).’ Taken from Qiagen RNeasy Mini Handbook. 
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2.9.3 Reverse Transcription 
The Reverse Transcriptase buffer (10xRT buffer), Random Primer, 
Deoxyribonucleotide Triphosphates (dNTP) and Reverse Transcriptase (RT) were 
provided in a ‘High Capacity cDNA Reverse Transcription Kit’ supplied by Applied 
Biosystems. To each microcentrifuge tube the following was added in this order:  
1. 10xRT buffer (2µl) for ensuring that the mixture is at the correct pH for reverse 
transcription to take place. 
2. Random Primer (2µl) used in real-time PCR for preparing the first strand of 
cDNA.  
3. Deoxyribonucleotide triphosphates (dNTP (1µl) are used to generate cDNA 
during PCR. Highly purified dNTP is required to achieve accurate results with 
real-time PCR.  
4. RNA (10µl), which is the sample RNA, obtained using the Qiagen RNA 
extraction protocol.  
5. Water (4.5µl) (Sigma-Aldrich, Sigma Molecular Biology Reagent) 
6. The contents of the tubes were the spun down in a microcentrifuge tube for 10 
seconds at 13.3x 104 rpm.  
7. The reverse transcriptase was added directly to the mixture with efficient 
mixing. This enzyme should be kept in the freezer just before use to prevent 
denaturing. All other materials that have been used for reverse transcription 
were kept on ice.  
8. To provide the ideal conditions for the reaction to occur, the microcentrifuge 
tubes were placed in heat blocks at 37°C.  
 
 
 
 
 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%$!"()%&'(*+%,%$!!!!!!!!!!!!!!!!!!!!-.'/0!/$!1'/02!3(%0&'!!
! <5!
2.9.4 Making up the RSV and L32 probe  
Ribosomal protein L32 (RL32) is a human protein coded by the RPL32 gene. It is 
present in all cells and was the housekeeping gene in this experiment. The other probe 
used was the RSV probe, which measured the level of human RSV N gene expression.  
 
A figure is provided for the primers used for RSV N gene detection (Figure 2.2.1) 
(156).  
 
 
Figure 2.2.1: The primers used for PCR RSV N gene expression. These are the 
primer sequences that are used for detection of RSV N gene expression by real-time 
PCR. It shows the primer and probe names, sequences and nucleotide position for each 
(156).  
 
The RSV and L32 (bought from Life Technologies as pre-developed assay) probes were 
provide by Sigma chemical company and are custom synthesised. The RSV probe was 
designed by Dewhurst-Maridor and made by Sigma (156). The RSV probe was labelled 
with FAM and TAMRA dyes. The RSV primers were synthesised by Sigma. The L32 
probe was already made ready for addition to the Taqman® Gene Expression Master 
Mix. To make the RSV probe, the following was added to a microcentrifuge tube: 
• 10µl of RSV AF (forward) 
• 10µl of RSV AR (reverse) 
• 40µl of RSV FAM 
• 40µl of RNAse free water (Fisher) 
 
Both the L32 and RSV probes were mixed with Taqman® Gene Expression Master Mix 
(Life Technologies). The Taqman® Gene Expression Master Mix contains buffers, 
dNTPs, internal reference dye (dye that provides an internal reference to which the 
reporter dye signal can be normalized during data analysis) and hot-start DNA 
polymerase that is essential for powering real-time PCR(157). 
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In one tube the RSV probe was mixed with Taqman® Gene Expression Master Mix. In 
the other microcentrifuge tube the L32 probe was mixed with Taqman master mix. For 
example if the probes were made for 6 samples then in each microcentrifuge tube there 
would be 160 Taqman® Gene Expression Master Mix and 16 of RSV or L32 probe. 
These volumes chosen were in surplus to ensure that there was enough Taqman master 
mix and probes for each sample, accounting for any pippetting errors.  
 
2.9.5 Polymerase Chain Reaction (PCR)  
 
2.9.5.1 Background  
 
Polymerase Chain Reaction (PCR) was developed by Kary Mullis in 1983 and is used 
to amplify copies of a chain of DNA in order to produce thousands of copies of a 
particular DNA sequence (158).  The technique that was applied in this project was real-
time PCR. This technique is also referred to as quantitative real-time PCR (qPCR), 
which was first made commercially available to Applied Biosystems in 1996 (159).  
 
2.4.5.2 Real-Time PCR  
Real-time PCR (is used for a broad range of applications including genotyping, 
pathogen detection, single nucleopeptide (SNP) analysis, pathogen detection, and 
quantitative gene expression analysis. The combination of real-time polymerase chain 
reaction with reverse transcription enables quantification of messenger RNA (mRNA) 
and microRNA (miRNA)(156).  
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Real-time PCR measures amplification of DNA strands in real-time without the need to 
process products using gel-based analysis after PCR has taken place, as seen in 
traditional PCR. Real-time PCR is more precise than traditional PCR and includes ultra-
rapid cycling, which takes 30 minutes to 2 hours. Another benefit of real-time PCR is 
that it allows the researcher to better determine the amount of DNA in the sample before 
the amplification by PCR (160).  
 
 A summary of the advantages of real-time PCR are (161): 
1. Increased dynamic range of detection. 
2. No post-PCR processing. 
3. Detection is capable down to a 2-fold change. 
4. Collects data in the exponential growth phase of PCR. 
5. An increase in reporter fluorescent signal is directly proportional to the number of 
amplicons generated. 
6. The cleaved probe provides a permanent record amplification of an amplicon. 
 
During a PCR reaction the sample DNA made from RNA taken from sample cells 
undergoes amplification. Amplification occurs in cycles during which the original DNA 
serves as a template for new copies of DNA to made. In real-time PCR there is a 
maximum of 40 amplification cycles (Figure 3.1). Amplification is exponential because 
for each cycle, the DNA made in previous cycle acts as a template. Real-time PCR 
reactions are characterised by the point in time during cycling when amplification of a 
target is first detected than the amount of target accumulated. The higher the starting 
copy of nucleic acid, the sooner the significant fluorescence increase is observed(162).    
 
Real-time PCR can be used to detect the level of RSV N gene expression from samples 
that have had RSV added. Samples, which have a greater RSV MOI, would be expected 
to have greater levels of RSV N gene expression, as more RSV particles would have 
been added to a set number of cells. All samples analysed by PCR were done in 
duplicate. After the data was collected these values were meand. The purpose of 
carrying out PCR is to provide evidence consistent with RSV infection of A549 cells 
indicating that experiments had been carried out accurately.  
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2.4.5.3 The Principles of the Polymerase Chain Reaction  
There are four phases in total throughout the PCR amplification(159): 
1. Baseline – during this stage exponential amplification is taking place despite no 
signal being released. The amplification levels are below those that can be 
detected by the Real-Time PCR.  
2. Exponential –the product should double exactly per cycle to produce a number of 
amplicons assuming that the asay is a 100% efficient. During this phase the real-
time PCR quantifies the amplicons. 
3. Linear–as the reaction substances are consumed the efficiency of amplification is 
reduced.  
4. Plateau – reaction ceases and no more products synthesised for remaining cycles. 
 
There are three components to the Real-Time PCR instrument (159):  
1. Light source – establishes receptor dye range detected by instrument. 
2.Detection system– determines the spectral range and sensitivity of assay. 
3.Thermocycling mechanism – monitors speed that assay is run and temperature 
changes between each well.  
 
 
The threshold level is the point at which the fluorescent signal is detected, above the 
background. The threshold level line is set during the exponential phase. Once the 
sample reaches this level, the cycle number is quantified and this is the result obtained 
from the real-time PCR – Cycle Threshold (Ct) (159). 
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2.4.5.4 Loading PCR plate 
The microcentrifuge tubes were taken out of the heat block and placed temporarily on 
ice. Water (50µl) (Sigma pure water, molecular biology reagent) was added to each 
sample so that there would be enough of each sample to load into each well of the 96-
well PCR plate (Starlab).  
 
In each PCR well the following was added: 
• 1.25µl of probe (RSV or L32). 
• 12.5µl of Taqman® Gene Expression Master Mix. 
• 11.25µl of sample diluted in RNase free water. 
 
The first 2 rows of L32 were allocated for the L32 probe and the next 2 for the RSV 
probe. Therefore, both samples for each probe were done in duplicate.  
 
An example diagram of the layout of PCR plate is shown below where the 3 RNA 
samples were taken from control (non-infected/NI) A59 cells sample, RSV infected 
cells (RSV) and RSV infected cell treated with Palivizumab (P) (Figure 2.2.2). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.2:  Example layout of PCR plate where NI= control, R= RSV infected, P 
= palivizumab added to RSV.  
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The PCR plate was covered with a film and the plate was spun to ensure that all of the 
contents were at the bottom of the w ells. The plate was put into an Applied Biosystems 
7300 Real-Time PCR reader. Real-time PCR computer software provided a plate layout 
where each sample and the corresponding probe added was labelled. The correct 
temperature cycle for the PCR to work efficiently was set. This depended on the 
TaqMan® Gene Expression Master Mix used which was from Applied Biosystems. The 
real-time PCR was run for 40 cycles, for approximately 2-3 hours. The amplification 
curves were monitored every 30 minutes. An example, of the amplification curves 
obtained from real-time PCR is shown (Figure 2.2.3). 
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Figure 2.2.3 Measurement of RSV N gene expression by real-time PCR. 
Explanation provided by Life Technologies (163). Each line represents a samples 
amplification curve. The x-axis shows the number of amplification cycles that each 
sample has undergone. The y-axis, delta Rn is the magnitude of the signal generated by 
a given set of PCR conditions. The horizontal red line is the threshold. The threshold 
line can be set arbitrarily but must be set in a region associated with exponential growth 
of PCR product. This region should be where the precision of the replicates is highest, 
which is usually the middle of the exponential phase as shown. Once the threshold line 
has been set, then the Ct (threshold cycle) value can be obtained for each sample. The 
Ct is the intersection between the amplification curve and threshold line to give a cycle 
number. It is the Ct values that are used to calculate the level of RSV N gene expression 
(163, 164).  
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2.4.5.5 PCR RSV N Gene Data Analysis  
The RSV N gene expression based on RSV ct values was calculated in 2 steps: 
1) The mean Ct value for L32 expression of the sample minus the mean ct value for 
RSV expression of the same sample. 
This was done to normalise the PCR data. This calculation allowed correction for some 
of the samples potentially having more mRNA and therefore cDNA within them. 
2) 2 to the power of n, where n = value obtained from step 1. 
This is the conversion from Ct values to fold differences. This particular calculation is 
because every cycle is a 2-fold change. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%$!"()%&'(*+%,%$!!!!!!!!!!!!!!!!!!!!-.'/0!/$!1'/02!3(%0&'!!
! 4==!
3. Results 
 
3.1 Overview of Experiments Carried Out  
The initial aim of this investigation was to determine whether RNF168 expression was 
affected by RSV infection of A549 cells. A preliminary RSV MOI titration experiment 
was carried out at 4 hours post RSV infection to determine if RSV was affecting 
RNF168 expression. Changes in expression were noted resulting in this experiment 
being repeated 2 further times. To provide supporting evidence that A549 cells had been 
productively infected with RSV, the samples in each experiment were analysed for RSV 
N gene expression by real-time PCR. Further evidence to support infection was 
provided by measuring the concentration levels of IL-6 and IL-8 in samples by 
Sandwich ELISA. To show that IL-8 was being released from cells in response to RSV 
infection, the concentration of IL-8 was compared to the IL-8 concentration of the RSV 
prep added to A549 cells.  
 
RSV MOI titration experiments were then carried out at 24 hours to see what effect a 
comparatively longer duration of infection would have on RNF168 expression. 24 hours 
RSV experiments were repeated 3 times. To provide supporting evidence that A549 
cells had been correctly infected with RSV, the samples in each experiment were 
analysed for RSV N gene expression by real-time PCR. Further evidence to support 
infection was provided by measuring the concentration levels of IL-6 and IL-8 in 
samples. The RNF168 expression values for the three experiments were meand and 
standard error of the mean calculated. The RNF168 expression values for all 3 
experiments were then calculated relative to the control.  The primary purpose of 4 and 
24 hours experiments were to determine whether there was a relationship between RSV 
MOI and RNF168 expression at these time points.  
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To provide supporting evidence for both 4 and 24 hours titration experiments a RSV 
infection time-course was done. This was primarily to identify if there was a 
relationship between duration of RSV infection and RNF168 expression. Changes in 
RNF168 expression had been seen at both 4 and 24 hours for cells with a RSV MOI of 
1:1. As a result, cells were infected with RSV at MOI 1:1 and protein samples harvested 
at time points of 0, 2, 4, 6, 24 and 48 hours of RSV infection. 0 hour was a starting 
control where the cells had not been infected with RSV and was harvested immediately 
after all other samples of A549 cell had been infected. There was a paired control for all 
other time points of RSV infection.  
 
As changes in RNF168 expression were seen in RSV infected cells further 
investigations were carried out with IFN-! and polyI:C. This was to gain an 
understanding of the mechanism by which RNF168 expression was affected by RSV. 
Two titration experiments involving IFN-! stimulation at varying concentrations for 4 
and 24 hours were carried out 3 times each. The concentration of IFN-! used ranged 
from 1-100ng. This was to see whether RNF168 expression was affected by the time 
and concentration of IFN-! stimulation. Furthermore, any change in RNF168 
expression may suggest a relationship between IFN-! and RSV infection at the same 
time points. To provide further supporting evidence for a possible relationship between 
duration of IFN-! stimulation and RNF168 expression an IFN-! time-course 
experiment was done. In this experiment cells stimulated with IFN-! were harvested at 
0, 2, 4, 6, 24 and 48 hours. 0 hours was taken to be a starting control where the cells 
were not stimulated with IFN-! and harvested immediately after all other sample cells 
had undergone IFN-! stimulation. Every other time point had a paired control. Samples 
were used to run a Western Blot. Therefore, evidence from these experiments could 
implicate IFN-! in the RNF168 expression pathway.   
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A time-course experiment was carried out with polyI:C. A549 cells were stimulated 
with 50ng/ml polyI:C and harvested at 0, 2, 4, 6, 24 and 48 hours. Again 0 hours was 
taken to be a starting control where the cells were not stimulated with polyI:C and 
harvested immediately after all other sample cells had undergone polyI:C stimulation. 
This experiment time point had paired control. Samples were used to run a Western Blot 
to measure RNF168 expression. This experiment involving polyI:C was carried out to 
see if TLR3 was implicated in the RNF168 pathway when cells are infected with RSV.  
 
To show that RSV was responsible for affecting RNF168 expression directly and not 
any other factor, A549 cells were treated with palivizumab and RSV (MOI 1:1) for 24 
hours. This sample was compared to a sample infected with RSV MOI 1:1 for 24 hours 
and a 24 hours control sample through measuring RSV N gene expression and Western 
Blot analysis for RNF168 expression.  
 
It should be noted that when measuring RNF168 expression in all experiments in this 
investigation, the values recorded were relative to the loading control !-actin. The 
values for RNF168 expression from experiments that had been carried out 3 times were 
meand to given an overall interpretation of how RSV or IFN-! affected RNF168 
expression. The standard error of the mean was calculated to establish the precision of 
values obtained. For all experiments, which measured RNF168 expression that had been 
carried out 3 times, RNF168, expression values were calculated relative to the control. 
As a result, the control value becomes 1, which in this case was taken to be 100%. The 
percentage increase or decrease in RNF168 expression could then be determined 
relative to the control.   
 
The samples from the same experiment for 4 hours post RSV infection were analysed 
for IL-8 and IL-6 concentrations in addition to RSV N gene expression and RNF168 
expression (Table 3.1.1). One set of samples from the same experiment for 24 hours 
post RSV infection was measured for IL-8 and IL-6 concentrations in addition to RSV 
N gene expression and RNF168 expression. The same samples in RSV time-course 
experiment was analysed for IL-8 concentration, RSV N gene expression and RNF168 
expression.  
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%$!"()%&'(*+%,%$!!!!!!!!!!!!!!!!!!!!-.'/0!/$!1'/02!3(%0&'!!
! 4=6!
 
A CXCL5 Sandwich ELISA was carried out for supernatants taken from A549 cells that 
had RSV time-course infection for time point 0, 2, 4, 6, 24 and 48 hours. Again time 0 
hours was a starting control and was harvested immediately after all other samples had 
undergone RSV infection. Each time point had a paired control to see whether time 
itself was influencing the amount of CXCL5 released from A549 cells.   
 
Statistical analysis was done by Student T Test (two-tailed) to determine whether there 
were any statistically significant differences between the control and infected or 
stimulated samples. Statistical analysis was carried out on experiment that had been 
carried out 3 times, which were: 
• 4 hours RSV titration data  
• 4 hours IFN-! data  
• 4 hours real-time PCR data 
• 4 hours IL-6 data 
• 4 hours IL-8 data  
• 24 hours RSV data  
• 24 hours IFN-! data  
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3.2 Measurement of RNF168 at 4 hours Post Infection 
 
A total of 3 experiments were carried out where the same samples in each experiment 
underwent real-time PCR, Sandwich ELISA and Western blot analysis. The table below 
links the data obtained for each experiment with regards to these techniques. 
 
Table 3.1.1:  Real-time PCR, Sandwich ELISA and Western Blot Experiments for 
each Sample 
 
Experiment PCR Sandwich 
Elisa (IL-
6) 
Sandwich 
ELISA 
(IL8) 
Western 
Blot for 
RNF168 
Expression 
RNF168 
Expression 
Relative to 
Control 
1 Figure (a) Figure (a) Figure (a) Figure (a) Figure (a) 
2 Figure (b) Figure (b) Figure (b) Figure (b) Figure (b) 
3 Figure (c) Figure (c) Figure (c) Figure (c) Figure (c) 
  
When comparing the data from all of the different techniques applied it was clear that 
the cells were being infected with productively for all 3 experiments. This was exhibited 
by high levels concentration of Il-8 and IL-6 as well as high levels of RSV N gene 
expression for samples infected with high RSV MOI in comparison to controls in each 
experiment. 
3.2.1. The Effect of RSV Infection of A594 cells for 4 hours on RSV N Gene 
Expression  
 
RNA harvested from samples that had undergone a 4 hours RSV MOI titration were run 
on real-time PCR in duplicate for RSV N gene and L32 a housekeeping gene. The Ct 
values derived from each sample duplicate are shown in the table below (Tables 3.3 and 
3.4). 
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Table 3.1.2:  Step 1 Calculate the Mean L32 Ct values for 4 hours RSV MOI 
Titration Experiment  
 
Multiplicity of 
Infection of RSV 
particles to A549 
cell (MOI) where 
NI=non-infected 
control 
1-L32 Ct 
Values 
2-L32 Ct 
Values 
Mean L32 Ct 
values 
NI 22.93 21.79 22.36 
0.025 22.94 22.62 22.79 
0.25 22.17 21.42 21.80 
0.5 22.78 20.57 21.68 
1 21.92 19.44 20.68 
 
 
 
 
 
Table 3.1.3:  Step 2 Calculate the Mean RSV N gene Ct values for 4 hours RSV 
MOI Titration Experiment  
Multiplicity of Infection 
of RSV particles to A549 
cell (MOI) where NI= 
non-infected control 
1-RSV N 
gene Ct 
Value 
2-RSV N 
gene Ct 
Value 
Mean RSV 
N gene Ct 
Value 
NI 0 0 0 
0.025 36.28 27.45 31.86 
0.25 30.63 23.59 27.11 
0.5 26.40 21.68 24.04 
1 24.25 19.89 22.07 
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The RSV values are subtracted from the L32 Ct mean values. This was to determine the 
level of true RSV N gene expression for each sample. These values were then inputted 
as the n value when calculating 2n. This was done to account for the exponential growth 
of the sample every amplification cycle (Table 3.5).  
 
Table 3.1.4: Calculations for the Relative Expression of RSV N Gene to L32 for 4 
hours RSV MOI Titration Experiment 1 (Figure 3.1.1 (c)) 
Multiplicity of 
Infection 
(MOI) where 
NI=Non-
infected 
Step 1: Mean 
RSV 
Step 2: Mean 
L32 
Step 3: L32-
RSV (n value) 
2 n 
NI 0 22.36 -22.36 1.85x 10-7 
 
0.025 31.86 22.78 -9.07 1.84 x 10-3 
 
0.25 27.11 21.80 -5.31 0.03 
0.5 24.04 21.68 -2.36 0.19 
1 22.07 20.68 -1.38 0.38 
 
The 2n values obtained from the table above there plotted (Figure 3.1.1 (c)). The 2n 
values were plotted on graphs (3.1.1). 
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(b) 
 
 
 
(c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.1: RSV N gene expression in A549 cells undergoing RSV infection for 4 
hours. A549 cells were infected with RSV of increasing MOI for 4 hours. The RNA 
was harvested from these samples and real-time PCR carried out. This experiment was 
carried out 3 times. 
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All 3 experiments have shown increasing RSV infection with increasing MOI. Controls 
(NI) gave the lowest level of RSV N gene expression in all 3 experiments (Figure 
3.1.1). An MOI of 1:1 gave the highest value of RSV N gene expression in all 3 
experiments (Figure 3.1.1). However, the range of values varied between experiments 
with the highest values ranging from a 0.38 in one experiment (Figure 3.1.1 (c)) to 1.52 
in another (Figure 3.1.1 (b)). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.2: Combined graph of all three experiments (Figure 3.1.1) of RSV 
infection of A549 cells for 4 hours. The results of the 3 experiments were combined 
into a graph to showing a clear comparison between the values obtained.  
 
 
Experiment 1 recorded the highest level of RSV N gene expression whereas experiment 
3 had the lowest levels across all samples (Figure 3.1.2). The control gave the lowest 
level of RSV N gene expression in all 3 experiments (Figure 3.1.2). An MOI of 1:1 
gave the highest value of RSV N gene expression in all three experiments (Figure 
3.1.2). At MOI 1:1 the range of values varied between experiments with the highest 
values ranging from a 0.38 in experiment 3 to 1.51 in experiment 1. 
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Figure 3.1.3: PCR data showing mean of 3 experiments of RSV N gene expression 
for A549 cells infected with RSV for 4 hours. An mean of all three experiments was 
calculated with precision noted by standard error of the mean error bars.   
 
Table 3.1.5: P-values for 4 Hours RSV infections to determine whether there was 
any statistical significant (p<0.05) difference between samples and the control for 
RSV N gene expression 
 
 
 
 
 
Mean values show that as the MOI increases the level of RSV N gene expression 
increases. The lowest level of RSV N gene expression is in the control at 7.9 x 10-5. The 
highest value was at MOI 1:1 at 1.04. The level of accuracy of experiments decreases 
with MOI as shown by the standard error bars increasing in size (Figure 3.1.3). 
Therefore, the MOI of 1:1 value is the least precise given that it has the largest standard 
error of the mean value. The difference in RSV N gene expression for the control in 
comparison to infected samples is not statistically significant (p<0.05) (Table 3.1.5). 
The greatest difference amongst infected samples for RSV N gene expression in 
comparison to the control was RSV MOI 1:1 (p=0.09) (Table 3.1.5). 
RSV MOI (n:1) P Value 
0.025:1 0.24 
0.25:1 0.18 
0.5:1 0.15 
1:1 0.09 
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3.2.2 Effect of 4 Hours Post RSV Infection on Interleukin- 6 (IL-6) Concentration 
Levels  
The following table shows the numerical values IL-6 concentration (pg/ml) taken from 
a Sandwich ELISA of A549 cells infected at 4 hours (table 3.6). 
 
Table 3.1.6: Example of Sandwich ELISA IL-6 Concentration Values for 4 hours 
RSV Infection  
Multiplicity of 
Infection (1:n) 
(Where NI is non- 
infected cells) 
Result 1 IL-6 
Concentration 
(pg/ml) 
Result 2 IL-6 
Concentration 
(pg/ml) 
Mean (pg/ml) 
NI 16.60 11.26 13.93 
0.025 78.90 64.55 71.73 
0.25 500.89 486.79 493.84 
0.5 930.43 937.50 933.97 
1 1341.13 1494.45 1417.79 
 
 
Values such as these are plotted on graphs (Figure 3.1.7). 
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(b) 
 
 
 
 
 
 
 
 
 
 
 
(c) 
 
 
Figure 3.1.4: The concentration levels of IL-6 produced from 4 hours RSV infected 
A549 cells. A549 cells were grown in 24-well plates and infected with RSV at MOI 
titration experiment for 4 hours duration. This experiment was carried out 3 times. The 
supernatant from these samples was taken and used to run a Sandwich ELISA.  
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In all 3 experiments as the MOI increases, the concentration of IL-6 increases (Figure 
3.1.4). The lowest concentration of IL-6 was present in the control in all 3 experiments 
(Figure 3.1.4). The concentration of IL-6 is greater in all RSV infected samples in 
comparison to the controls (Figure 3.1.4). The highest concentration of IL-6 is seen in at 
MOI 1:1 ranging from 766.55 (Figure 3.1.4 (c)) to 1417.79 pg/ml (Figure 3.1.4 (a)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.5: Combined graph of 3 identical experiments (Figure 3.1.4) showing 
the levels of IL-6 produced from 4 hours RSV infected A549 cells. Values of the 3 
experiments were combined together to provide a clear comparison between data 
obtained. 
 
When comparing experiments to one another the range of IL-6 concentrations vary 
across experiments (Figure 3.1.5). The highest values were in experiment 1 whereas the 
lowest values were in experiment 3 across all samples (Figure 3.1.5).  
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The highest value in all 3 experiments is recorded at MOI 1:1,ranging from 
1417.79pg/ml (experiment 1) to 766.54pg/ml (experiment 3) (Figure 3.1.5). The lowest 
values across all 3 experiments are recorded for the control (Figure 3.1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.6: Mean IL-6 values taken for all three experiments (Figure 3.1.4.) 
where A549 cells undergo 4 hours RSV infection with standard error bars. An 
mean of the experiments was taken with standard error calculated to determine the 
accuracy of the experiments carried out.  
 
Table 3.1.7: P-values for IL-6 to determine whether there was any statistical 
significant (p<0.05) difference between samples and the control  
 
RSV MOI (n:1) P Value 
0.025:1 0.006 
0.25:1 0.052 
0.5:1 0.025 
1:1 0.042 
 
As RSV MOI increases, the concentration of IL-6 increases (Figure 3.1.6). All RSV 
infected samples have a greater concentration of IL-6 than the control, which had the 
lowest levels (Figure 3.1.6). The lowest level for the control is 10.35 and the highest 
value at MOI 1:1 995.64 (Figure 3.1.6).  The precision of the values obtained decreases 
as MOI increases as shown by the size of the standard error bars which were the largest 
at MOI 1:1 and the least accurate value (Figure 3.1.6).  
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In comparison to the control, the IL-6 concentration levels are significantly greater 
(p<0.05) at RSV MOIs 0.025:1 (p=0.006), 0.5:1(p=0.025) and 1:1 (p=0.042) (Table 
3.1.7). 
 
 
 
3.2.3 Effect of 4 Hours Post RSV Infection on Interleukin- 8 (IL-8) Concentration 
Levels 
 
 
 
Table 3.1.8: Example of Sandwich ELISA IL-8 Concentration Values for 4 hours 
RSV MOI titration experiment  
 
Multiplicity of 
Infection (1:NI) 
Where NI is non- 
infected cells 
Result 1: IL-8 
Concentration 
(pg/ml) 
Result 2: IL-8 
Concentration 
(pg/ml) 
Mean: IL-8 
Concentration 
(pg/ml) ((Result 1 
+Result 2)/2) 
NI 183.22 391.56 287.39 
0.025 417.09 365.96 391.53 
0.25 391.56 822.34 606.95 
0.5 645.16 763.19 704.17 
1 805.43 839.26 822.35 
 
 
Values such as these are plotted on graphs (Figure 3.1.7). 
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(c) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.7: The effect of a 4 hours RSV infection on the levels of IL-8 released 
from A549 cells. A549 cells were infected with RSV at 4 hours as an MOI titration 
experiment. The supernatant was taken of these samples and run for an IL-8 Sandwich 
ELISA. This experiment was carried out 3 times. 
 
 
All RSV infected samples had higher concentrations of IL-8 than the control across two 
experiments (Figure 3.1.7). However, in one experiment the control had IL-8 
concentration of 261.12 pg/ml, which was greater than RSV MOI 0.025:1 sample, 
which had an IL-8 concentration 212.8pg/ml (Figure 317 (a)). In another experiment the 
concentration levels for the control and MOI 0.025:1 were almost identical (Figure 3.1.7 
(c)).  As the MOI of RSV increases, the concentration of IL-8 increases in two 
experiments (Figure 3.1.7 (a) and (b)). However, this is not true in one experiment 
where the highest IL-8 concentration value is at 0.5:1 after which the IL-8 concentration 
decreases (Figure 3.1.7 (c)).  
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Figure 3.1.8: Combined graph of 3 experiments (Figure 3.1.7) measuring IL-8 
concentrations for 4 hours RSV infection of A549 cells. The data was combined so 
that there could be a clear comparison between experiments. 
 
 
 
 
Across all samples the highest concentration levels IL-8 are in experiment 2 whereas 
experiment 1 had the lowest (Figure 3.1.8). In two of the experiments the highest 
concentration level of IL-8 was at a MOI of 1:1, which was 607.05pg/ml for experiment 
1 and 822.34pg/ml for experiment 3 (Figure 3.1.8). Experiment 3 had the highest 
concentration levels of IL-8 recorded at RSV MOI 0.5:1, as 1798.53pg/ml (Figure 
3.1.8). This was the highest IL-8 concentration recorded across all three experiments 
(Figure 3.1.8).  
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Figure 3.1.9: Mean IL-8 concentration for 4 hours RSV infection of A549 cells with 
standard error bars. A mean value of all 3 experiments (Figure 3.1.7) was calculated 
with standard error bars to determine the accuracy of values.  
 
Table 3.1.9: P-values for IL-8 to determine whether there was any statistical 
significant (p<0.05) difference between samples and the control  
RSV MOI (n:1) P Value 
0.025:1 0.72 
0.25:1 0.08 
0.5:1 0.20 
1:1 0.03 
 
All infected samples have a greater concentration of IL-8 in comparison to the control 
(Figure 3.1.9). From the means calculated higher RSV MOIs given greater 
concentrations of IL-8 (Figure 3.1.9). The highest concentration levels of IL-8 are 
recorded at 0.5:1 as 996.7 pg/ml (Figure 3.1.9). This value has the greatest standard 
error of the mean error bar suggesting that this value is the least accurate (Figure 3.1.9).  
The IL-8 concentration was significantly greater than the control at MOI 1:1 (P=0.03, 
where p<0.05 is statistically significant). 
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Figure 3.2.1: Comparison between the total concentrations levels of IL-8 and 
amount of IL-8 in the RSV prep. The purpose of this experiment was to show that 
RSV infection leads to production of IL-8 from A549 cells accounting for IL-8 
concentrations recorded instead of the IL-8 present in the RSV prep. In addition to 
A549 cells that had been infected with RSV as a MOI titration experiment, RSV prep 
(MOI 1:1) was added to a well in the 24-well plate that did not contain A549 cells. This 
well was kept under the same condition as all other sample. The supernatant was taken 
from all of these wells after 4 hours and used to run an IL-8 Sandwich ELISA. Once the 
IL-8 concentration for the RSV prep only sample had been measured, this value was 
divided to show the IL-8 concentration for RSV prep added to samples that were 
infected at a lower MOI.  
 
For all samples the concentration of IL-8 in the RSV prep added to A549 cells was 
lower than the total IL-8 concentration that the same sample produced (Figure 3.2.1). 
For MOI 1:1 the concentration of IL-8 was 532pg/ml greater for MOI 1:1 than the RSV 
prep. The biggest difference in IL-8 concentration between RSV prep and total IL-8 
concentration was for MOI 0.5:1, which was 559pg/ml. 
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3.2.4 Western Blot data: The Effect of 4 Hours RSV infection on RNF168 
Expression  
 
The table below shows the values taken from densitometry carried out on western blot 
images of RNF168 for samples of A549 cells, which had undergone 4 hours RSV 
infection (Table 3.8). 
 
 
Table 3.2.1: Example Densitometry values of Western Blot Image for RNF168 and 
Actin for 4 Hours RSV MOI Titration of A549 Cells 
 
 
Multiplicity of 
Infection 
(1:NI) 
Where NI is 
non- infected 
cells 
RNF168 Actin RNF168/Actin Divided by 
Control (0.32) 
NI 2198.04 6931.43 0.32 1 
0.025 2565.87 7123.43 0.36 1.13 
0.25 2775.28 6822.13 0.41 1.28 
0.5 3420.58 6883.01 0.50 1.56 
1 3104.34 5646.11 0.55 1.72 
 
 
Values such as these were plotted in graphs (Figure 3.2.1).  
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(c) 
               
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2. Level of RN168 expression for A549 cells that have undergone 4 
hours RSV infection. A549 cells were infected with RSV for 4 hours as MOI titration 
experiment. This experiment was carried out 3 times. The proteins from these cells were 
harvested and used to run a Western Blot. The images underwent densitometry analysis 
using ImageJ software. 
 
In comparison to the control all RSV samples have shown an increase in RNF168 
expression (Figure 3.2.2). In two experiments as the MOI of RSV increases, the level of 
RNF168 expression also increases (Figure 3.2.2. (a) and (b)). However in one 
experiment, the level of RNF168 expression increases from control to MOI 0.025:1 and 
stays at a relatively similar level as MOI increases (Figure 3.2.2. (c)).  
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Figure 3.2.3: Combined graph of 3 replicate experiments (Figure 3.2.2) measuring 
the level of RNF168 expression from A549 cells infected with RSV for 4 hours. The 
data from 3 experiments (Figure 3.2.2) was combined so that there could be a clear 
comparison between experiments. 
 
 
The highest level of RNF168 expression was at an MOI of 1:1 in experiment 2, which 
was 0.96. In two of the experiments the highest level of RNF168 was at MOI 1:1 at 0.96 
and 0.55 for experiments 2 and 3 respectively (Figure 3.2.3). For experiment 1 the 
highest level of RNF168 expression was at MOI 0.025:1 at 0.59 (Figure 3.2.3). Only 
experiment 2 and 3 show an increasing concentration of IL-8 with increasing MOI. The 
lowest IL-8 concentration for all 3 experiments was the control (Figure 3.2.3).  
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Figure 3.2.4: Graph showing mean values of RNF168 expression from 3 replicate 
experiments (Figure 3.2.2) where A549 cells have undergone RSV infection for 4 
hours. Mean values were calculated to give an overall impression of the relationship 
between RSV and RNF168 expression for 4 hours RSV infection. 
 
Table 3.2.2: P-values for 4 Hours RSV to determine whether there was any 
statistical significant (p<0.05) difference between infected samples and the control 
in terms of RNF168 expression 
 
RSV MOI (n:1) P Value 
0.025:1 0.20 
0.25:1 0.12 
0.5:1 0.11 
1:1 0.13 
 
The mean values calculated from the 3 experiments shows that as RSV MOI increases, 
the level of RNF168 expression also increases (Figure 3.2.4). The highest value was at 
MOI 1:1 at 0.67 and the lowest was the control at 0.2 (Figure 3.2.4). The value at MOI 
was 1:1 as this has the largest standard error bar and was thus the least precise (Figure 
3.2.4). In comparison to the control there was no statistically significant difference 
(p<0.05) between the control and RSV infected samples (Table 3.2.1). The increase in 
RNF168 expression for 0.5:1 RSV in comparison to the control was more significant 
(p=0.11) when compared to other RSV infected samples (Table 3.2.1). 
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3.2.5. Western Blot data: The Effect of 4 Hours RSV infection on RNF168 
Expression Relative to Control 
 
(a) 
 
  
 
(b) 
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(c) 
 
 
Figure 3.2.5: Level of RNF168 expression relative to control for A549 cells infected 
with RSV for 4 hours. The values for all three experiments were calculated relative to 
the control.  This was to standardise for the yield and the number of cells in each 
sample.  
 
In comparison to the control all RSV samples have shown an increase in RNF168 
expression (Figure 3.2.5). The control had the lowest level of RNF168 expression in all 
three experiments (Figure 3.2.5). In two experiments as the MOI of RSV increases, the 
level of RNF168 expression also increases (Figure 3.2.5. (a) and (b)). The biggest 
increase in RNF168 expression was 759% and 73% at MOI 1:1 in comparison to the 
control (Figure 3.2.5. (a) and (b)). In another experiment the biggest increase in 
RNF168 expression was by 263% in comparison to the control at MOI 0.5:1 (Figure 
3.2.1. (c)).  
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Figure 3.2.6: Combined graph of 3 experiments (Figure 3.2.5) of RNF168 
expression relative to control for A549 cells infected with RSV for 4 hours. The data 
from 3 experiments (Figure 3.2.5) was combined to provide a clear comparison between 
experiments.  
 
Experiment 2 had the highest levels of RNF168 expression in all samples whereas 
experiment 3 had the lowest level of RNF168 expression (Figure 3.2.6). The highest 
levels of expression for RNF168 were seen at MOI 1:1 for experiments 2 and 3 at 8.58 
and 1.73 respectively (Figure 3.2.6). The highest level of RNF168 expression for 
experiment 1 was at MOI 0.025:1 at 3.59 (Figure 3.2.6).  
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Figure 3.2.7: Mean levels of RNF168 expression relative to control for A549 cells 
infected with RSV for 4 hours. Mean values from the 3 experiments (Figure 3.2.5) 
were calculated to provide an overall interpretation of the relationship between RNF168 
expression and 4 hours RSV infection.  
 
 
 
 
The biggest increase in RNF168 was at MOI 1:1 of 89% more than the control (Figure 
3.2.7).  It was noted that as the MOI increased, the percentage increase in RNF68 
expression also increased (Figure 3.2.7). The value that was least accurate was at MOI 
0.5:1 where the standard error of the mean is the greatest (Figure 3.2.7). 
 
 
3.3 Measurement of RNF168 Expression at 24 hours Post Infection 
 
One sample for 24 hours post RSV infection was measured for IL-8 and IL-6 
concentrations in addition to RSV N gene expression and RNF168 expression (Figure 
3.2.8, 3.2.9, 3.3.1 and 3.3.2 (b)). The Il-6, IL-8, RSV N gene data provides supporting 
evidence that RSV infection of A549 cells was carried out correctly. 
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3.3.1. The Effect of RSV Infection of A594 cells for 24 hours on RSV N Gene 
Expression  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.8: The level of RSV N gene expression in A549 cells infected with RSV 
for 24 hours. A549 cells were grown in a 24-well plate and infected with RSV as a 
MOI titration experiment. The RNA was harvested from these samples and used to run 
real-time PCR for RSV N gene expression. This experiment was carried out 3 times.  
 
 
All RSV infected cells have shown RSV N gene expression, which is greater than the 
control (Figure 3.2.8). The control sample had no RSV N gene expression. As the RSV 
MOI increases, the level of RSV N gene expression also increases between MOI 
0.025:1 and 0.5:1(Figure 3.2.8). The highest level of RSV N gene expression was at 
0.5:1 at 26.51. After RSV MOI 0.5:1 the level of RSV N gene expression decreases at 
MOI 1:1(Figure 3.2.8).  
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3.3.2. The Effect of 24 hours RSV Infection of A549 cells on IL-6 Concentration 
Levels 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.9: The concentration of IL-6 produced from A549 cells infected with 
RSV for 24 hours. A549 cells were infected with RSV over 24 hours as a MOI titration 
for 24 hours. The supernatant from these samples was run for an IL-6 Sandwich ELISA.  
 
The control sample had the lowest concentration of IL-6 57.49 pg/ml (Figure 3.2.9). In 
comparison to the control, all RSV infected samples had greater concentration level of 
IL-6 (Figure 3.2.9). The highest IL-6 concentration was at MOI 1:1 at 2003.24 pg/ml 
(Figure 3.2.9). As the RSV MOI increases the concentration of IL-6 increases (Figure 
3.2.9). 
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3.3.3. The Effect of 24 hours RSV infection of A549 cells on IL-8 Concentration 
Levels  
 
 
 
Figure 3.3.1: Concentration of IL-8 produced from A549 cells when infected with 
RSV for 24 hours. A549 cells were grown in a confluent 24-well plate were infected 
with RSV as a MOI titration experiment for 24 hours. The supernatant was taken from 
these samples and used to run an IL-8 Sandwich ELISA.  
 
 
In comparison to the control, it is clear that the concentration of IL-8 is higher in RSV 
infected samples (Figure 3.3.1). The lowest concentration of IL-8 is the control at 
1238.61pg/ml (Figure 3.3.1). The highest levels occurred with RSV MOI 1:1 at 
4062.21pg/ml (Figure 3.3.1). The general trend is increasing RSV MOI leads to a higher 
concentration of IL-8 (Figure 3.3.1). However, the RSV MOI 0.5:1 is the one exception 
to this as the IL-8 concentration at this MOI is 2968.99 pg/ml, which is lower than the 
MOI 0.25:1 that has an IL-8 concentration of 3539.41pg/ml (Figure 3.3.1).  
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3.3.4 Western Blot Data: The effect of 24 hours RSV infection on RNF168 
Expression  
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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(c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.2: The level of RNF168 expression from A549 cells that have been 
infected with RSV for 24 hours.  A549 cells were grown in 24-well plates and infected 
with RSV as a MOI titration experiment. The protein from the cells was harvested after 
24 hours and used to run Western blot for RNF168 expression.  
 
 
In all three experiments the level of RNF168 expression is the lowest at RSV MOI 1:1 
(Figure 3.3.2). In two experiments the highest level of RNF168 expression is at MOI 
0.025:1 at 1.65 (Figure 3.3.2 (a)) and 2.6 (Figure 3.3.2 (b)). In the other the greatest 
RNF168 expression level occurs at 0.35 for the control (Figure 3.3.2 (c)).  In all 3 
experiments the RNF168 expression decreases between MOIs 0.025:1 to 1:1.  The 
lowest level of RNF168 expression across all experiments is at an MOI of 1:1 with the 
lowest value being 0.01 (Figure 3.3.2 (c)).   
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Figure 3.3.3: A combined graph of 3 experiments investigating the effect of 
infecting A549 cells with RSV for 24 hours.  The data from all three graphs (Figure 
3.3.2) was combined into a graph to provide a clear comparison between values.   
 
 
Experiment 3 had the lowest level of  RNF168 expression across all samples with the 
lowest being MOI 1:1 at 0.01 (Figure 3.3.3). Experiment 2 had the highest values of 
RNF168 with 2.6 at MOI 0.025:1 being the highest value (Figure 3.3.3).  The 
relationship between MOI and RNF168 expression are identical in experiments 1 and 2 
(Figure 3.3.3). These show that in comparison to the control RNF168 expression 
initially increases at a RSV MOI of 0.025:1 and then continues to decrease as MOI 
increases (Figure 3.3.3). However, experiment 3 shows RNF168 expression decreasing 
from control to RSV MOI 1:1(Figure 3.3.3).  
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Figure 3.3.4: Mean RNF168 expression values for 24 hours RSV infection with 
standard error bars. The values obtained for the 3 replicate experiments (Figure 3.3.2) 
involving the infection of A549 cells for 24 hours were meand and standard error of the 
mean calculated as represented by error bars. This gave the overall relationship between 
RNF168 and RSV at 24 hours. 
 
Table 3.2.3: P-values for 24 Hours RSV to determine whether there was any 
statistical significant (p<0.05) difference between samples and the control  
RSV MOI (n:1) P Value 
0.025:1 0.29 
0.25:1 0.41 
0.5:1 0.16 
1:1 0.14 
 
The lowest mean RNF168 expression value is the control at 0.8 (Figure 3.3.4). In 
comparison to the control, there is an increase in RNF168 expression for MOI 1:0.025 
at 1.21 which is the highest value (Figure 3.3.4). Thereafter, the level of RNF168 
expressions continues to decrease as MOI increases. The most inaccurate value is at 
MOI 0.025:1 because it has the largest standard error of the mean (Figure 3.3.4).  
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When comparing the infected samples with the control, the difference in RNF168 
expression is not statistically significant (p<0.05) (Table 3.2.2).In contrast, other 
infected samples MOI 1:1 showed the greatest difference in RNF168 expression when 
compared to the control (p=0.14) (Table 3.2.2). 
 
3.3.5 Western Blot Data: The effect of 24 hours RSV infection on RNF168 
Expression relative to control 
 
 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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(c) 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.5:  The level of RNF168 expression relative to control for A549 cells that 
have undergone 24 hours RSV infection. The level of RNF168 expression present in 
the three repeat experiments (Figure 3.2.2) was re-calculated relative to the control.  
This was to standardise the yield and number of cells per sample. 
 
In one of the experiments as the MOI increases the expression of RNF168 decreases by 
96% at MOI 1:1 (Figure 3.3.5 (c)). The highest value recorded for the same experiment 
was the control (Figure 3.3.5 (c)). In the other two experiments the highest value was at 
MOI 0.025:1 which showed an increase by 35% (Figure 3.3.5 (a)) and 96% (Figure 
3.3.5(b)) in comparison to the control. After MOI 0.025:1, the expression of RNF168 
decreases with increasing MOI (Figure 3.3.5 (a) and (b)). The lowest value for both 
these experiment shows a decrease at MOI 1:1 by 71% (Figure 3.3.5 (a)) and 65% 
(Figure 3.3.5(b)) in comparison to control.  
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Figure 3.3.6: Combined graph for the level of RNF168 expression relative to 
control in three experiments where A549 cells are infected with RSV for 24 hours. 
The values from the three experiments (Figure 3.3.5) were combined together to 
provide a clear comparison.  
 
Experiment 2 had the highest level of RNF168 expression for all samples (Figure 3.3.6). 
Experiment 3 had the lowest level of RNF168 expression for all samples (Figure 3.3.6). 
The lowest level of RNF168 expression was seen at MOI 1:1 for all samples in 
experiment 3 (Figure 3.3.6). Experiments 1 and 2 showed an increase of 35% and 96% 
in comparison to the control at MOI 0.025:1 (Figure 3.3.6). After MOI 0.025:1, 
RNF168 expression decreases in both experiments (Figure 3.3.6).   
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Figure 3.3.7: Mean value of RNF168 expression for A549 cells infected with RSV 
for 24 hours. The mean of RNF168 expression values taken from 3 experiments 
(Figure 3.3.5) was calculated with standard error of the mean displayed as error bars.  
 
 
 
From the mean values it is clear that the lowest level of RNF168 expression is present at 
an MOI of 1:1 at 0.23, which is a decrease of 77% in comparison to the control (Figure 
3.3.7). The highest level is at MOI 0.025 at 1.27, which is a 27% increase in comparison 
to the control (Figure 3.3.7). However, the standard error of the means for MOI 0.025:1 
is the largest suggesting that it is the least accurate value (Figure 3.3.7). 
 
 
 
3.4 Influence of time post infection on RNF168 gene expression 
The same sample was measured for RSV N gene expression and IL-8 concentration   in 
addition to RNF168 expression. The RSV N gene expression and IL-8 data provided 
supporting evidence that cells had been infected correctly and viral replication was 
greater for a longer duration of RSV infection.  
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3.4.1 The Effect of Duration of RSV Infection on RSV N gene Expression 
   
 
Figure 3.3.8: RSV N gene expression of samples of A549 cells, which have 
undergone RSV infection for 0, 2, 4, 6, 24 and 48 hours. A549 cells grown in a 24-
well plate were infected with RSV (MOI 1:1) for time points 0, 2, 4, 6, 24 and 48 hours. 
0 hours was a starting control which was harvested immediately after all other samples 
had been infected. The RNA harvested from RSV infected cells (not the paired control) 
was used to run real-time PCR for RSV N gene expression.  
 
At the 0 hours control no RSV N gene expression is detected (Figure 3.3.8). At all other 
times points for RSV infected samples there is RSV N gene expression (Figure 3.3.8). 
The level of RSV N gene expression is comparable for 2,4 and 6 hours samples (Figure 
3.3.8). However, at 24 hours the level of RSV N gene expression increases greatly by 
approximately 30 fold from 1.25 at 6 hours to 30.05 at 24 hours (Figure 3.3.8). Between 
24 and 48 hours, RSV N gene expression more than doubles to 78.69, which is the 
highest value (Figure 3.3.8)?  
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3.4.2 The Effect of Duration of RSV Infection on IL-8 levels  
 
 
 
 
 
 
Figure 3.3.9: IL-8 Sandwich ELISA for A549 cells infected with RSV for 0, 2, 4, 6, 
24 and 48 hours with paired controls. A549 cells grown in a 24-well plate were 
infected with RSV (MOI 1:1) for time points 0, 2, 4, 6, 24 and 48 hours paired with 
controls (sample of cells that were not infected) for each time point. 0 hours was a 
starting control which was harvested immediately after all other samples had been 
infected. The supernatant for each of these samples was removed and used to run an IL-
8 Sandwich ELISA comparing infected samples with controls.  
 
All RSV infected cells produced a higher concentration level than the control at the 
same time point (Figure 3.3.9). The lowest level of IL-8 was at the 0 hour starting 
control at 131.36 pg/ml (Figure 3.3.9).  When comparing control and RSV infected 
samples at 24 and 48 hours, RSV sample has more than doubled in concentration level 
of IL-8 at both of these time points (Figure 3.3.9). The highest concentration of IL-8 
was at 48 hours at 8209 pg/ml (Figure 3.3.9). 
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3.4.3 Western Blot Data: The Effect of Duration of RSV Infection on RNF168 
Expression 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
Figure 3.4.1: RNF168 expression for A549 cells infected with RSV for 0, 2, 4, 6, 24 
and 48 hours with paired controls. A549 cells were grown in a 24-well plate and 
infected with RSV at MOI 1:1.  For each RSV sample there was a paired control of non-
infected cells. The cells were harvested at 0, 2, 4, 6, 24 and 48 hours time points along 
with their paired control. 0 hour was a starting control with no RSV added and was 
harvested immediately after RSV had been added to all other samples of A549 cells. 
These samples were run for a Western blot. The images gathered were analysed using 
ImageJ software to obtain densitometry values. The 48 hours time point was not plotted 
as both results for control and infected samples did not develop sufficiently for 
densitometry to be done. 
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The highest level of RNF168 expression is the 24 hours control at 0.2 (Figure 3.4.1). 
The lowest level of RNF168 expression is for the 2 hour RSV infected sample at 0.048 
(Figure 3.4.1).  Excluding 24 hours, the 0 hour control had the next highest level of 
RNF168 expression at 0.11 (Figure 3.4.1). The RSV infected samples had the lowest 
levels of RNF168 expression in comparison to the controls at the same time point 
(Figure 3.4.1). The biggest difference between control and infected samples was at 24 
hours where the control was 0.16 greater than the infected sample (Figure 3.4.1). This 
difference was 0.16 (Figure 3.4.1). 
 
 
 
3.5. Measurement of RNF168 Expression for 4 Hours Interferon-beta 
stimulation  
 
3.5.1. Western Blot Data: The effect of Interferon beta Stimulation on RNF168 
Expression at 4 Hours  
(a) 
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(b)   
            
 
 
 
 
 
 
 
 
 
(c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.2: RN168 expression levels for A549 cells that have been stimulated with 
IFN-!  for 4 hours. A549 cells were grown in a 24-well plate and stimulated with IFN-
! as a titration experiment for 4 hours. The protein was then harvested from cells and 
used to run a western blot. The images produced were analysed for densitometry using 
ImageJ software.  
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In comparison to the control, the level of RNF168 expression was greater in all IFN-! 
samples. The highest level of RNF168 expression was at 50ng/ml in two experiments at 
1.51 (Figure 3.4.2 (a)) and 1.17 (Figure 3.4.2 (b)). In the other experiments the highest 
level of RNF168 expression was at 10ng/ml giving 0.36. 
 
 
 
 
 
 
Figure 3.4.3: Combined results from the 3 experiments involving IFN-!  
stimulation of A549 cells for 4 hours. The data from the 3 experiments (Figure 3.4.2) 
was combined into a graph to provide a clear comparison of the values obtained.  
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Experiment 3 has the lowest level of RNF168 expression across all samples whilst 
experiment 1 has the highest across all samples (Figure 3.4.3). The peak levels of 
RNF168 expression are seen at IFN-! concentration levels 10ng/ml and 50ng/ml for all 
3 experiments (Figure 3.4.3).  
 
 
Figure 3.4.4: Means level of RNF168 expression for A549 cells that have 
undergone IFN-!  stimulation for 4 hours with standard error bars. The mean 
RNF168 expression values from all 3 IFN-! experiments where standard error of mean 
was calculated to determine the accuracy of the mean values.  
 
 
Table 3.2.4: P-values for 4 Hours IFN-beta stimulation to determine whether there 
was any statistical significant (p<0.05) difference between stimulated samples and 
the control  
 
 
IFN-!  Concentration 
(ng/ml) 
P Value 
1 0.17 
5 0.17 
10 0.15 
50 0.14 
100 0.17 
 
The lowest value of RNF168 is the control at 0.27 and the highest value is for the 
50ng/ml sample at 1 (Figure 3.4.4). 
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 Between NI and 50ng/ml the expression of RNF168 increases as the concentration of 
IFN-! increases (Figure 3.4.4). The greatest inaccuracy for RNF168 expression values 
was seen between 5ng/ml and 50ng/ml as these values had the largest standard error 
bars (Figure 3.4.4).  
 
The comparison between IFN-! stimulated samples and the control shows that there is 
no statistically significant difference (P<0.05) (Table 3.2.4). When comparing IFN-! 
stimulated samples, the 50ng/ml seemed to have the most significant difference to the 
control (Table 3.2.4). 
3.5.2. Western Blot Data: The effect of Interferon beta Stimulation on RNF168 
Expression at 4 Hours relative to control  
(a) 
 
 
 
 
 
 
 
 
 
 
(b) 
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(c) 
 
Figure 3.4.5:  RNF168 expression relative to control for 4 hours IFN-!  stimulation 
of A549 cells. The level of RNF168 expression in the 3 IFN-! experiments (Figure 
3.4.2) calculated relative to the control. This was to standardise number of cells and 
yield of protein between samples. 
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Figure 3.4.6: Combined graph of RNF168 expression relative to control for A549 
cells that have been stimulated with IFN-!  for 4 hours. The graphs from the 3 IFN-! 
experiments (Figure 3.4.5) were combined together to provide a clear comparison 
between data.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.7: Mean RNF168 expression relative to control for A549 cells stimulated 
with IFN-!  for 4 hours with standard error bars.  Means of RNF168 expression for 
the 3 experiments were carried out and standard error of the means calculated as errors 
bars. The error bars show the accuracy of the mean values calculated.  
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3.6 Measurement of RNF168 Expression for 24 Hours Interferon-beta 
stimulation 
3.6.1. Western Blot Data: The effect of Interferon beta Stimulation on RNF168 
Expression at 24 Hours 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
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(c) 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.8: RNF168 expression for A549 cells stimulated with IFN-!  for 24 
hours. A549 cells were grown in a confluent 24-well plate and stimulated with IFN-! 
as a titration experiment for 24 hours. The protein from these cells was harvested and 
used to run a western blot. This experiment was carried out 3 times.  
 
 
 
 
In two of the experiments in comparison to the control the level of RNF168 expression 
is lower for 1ng/ml with values 0.057 (Figure 3.4.8 (a)) and 0.29 (Figure 3.4.8 (b)) 
being the lowest levels of RNF168 in both experiments. The highest level of RNF168 
expression was noted at IFN-! concentration 100ng/ml in the same two experiments as 
0.79 (Figure 3.4.8 (a)) and 1.15 (Figure (b)). In the other experiments the highest 
concentration of RNF168 expression was noted for control at 4.27 (Figure 3.4.8 (c)). 
The lowest level of RNF168 expression for this experiment is at 10ng/ml at 1.41(Figure 
3.4.8 (c)). 
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Figure 3.4.9: Combined graph of experiments for IFN-!  stimulation of A549 cells 
for 24 hours. The data from the 3 experiments (Figure 3.4.8) was combined so that a 
clear and direct comparison could be made.  
 
 
Experiment 3 had the highest level of RNF168 expression across all samples. 
Experiments 1 and 2 follow a similar pattern of RNF168 expression with a with an 
increasing RNF168 expression with higher concentration of IFN-!.  
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Figure 3.5.1: Mean values for IFN-!  stimulation of A549 cells for 24 hours. An 
mean value for the 3 experiments (Figure 3.4.8) was calculated. The standard error of 
the mean was also determined as the accuracy of the mean values.  
 
Table 3.2.5: P-values for 24 Hours IFN-!  to determine whether there was any 
statistical significant (p<0.05) difference between samples and the control  
IFN-!  Concentration 
(ng/ml) 
P Value 
1 0.25 
5 0.34 
10 0.38 
50 0.40 
100 0.60 
 
From the mean values calculated the lowest level of RNF168 expression is at 1ng/ml at 
0.75 (Figure 3.5.1). The highest level of RNF168 expression is the control at 1.81 
(Figure 3.5.1). Out of the IFN-! stimulated samples, the highest level of RNF168 
expression was at 100ng/ml at 1.16 (Figure 3.5.1).  
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The sample with the largest standard error of the mean value was the control suggesting 
that this value is the least precise (Figure 3.5.1). There was no statistically significant 
(p<0.05) difference between the IFN-! stimulated samples and control. The greatest 
difference among stimulated samples to the control was at 1ng/ml (p<0.25) (Table 
3.2.5). 
3.6.2. Western Blot Data: The effect of Interferon beta Stimulation on RNF168 
Expression Relative to Control at 24 Hours 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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(c) 
 
Figure 3.5.2: The level of RNF168 expression relative to control for cells stimulated 
with IFN-!  for 24 hours relative to the control. The level of RNF168 expression was 
calculated relative to the control to standardise for yield and number of cells from each 
sample. This experiment was carried out 3 times. 
 
Two experiments show an increase in RNF168 expression for IFN-! stimulated samples 
as IFN-! concentration increases (Figure 3.5.2 (a) and (b)). The other experiment shows 
RNF168 expression lower than the control for all IFN-! samples (Figure 3.5.2 (c)). Out 
of all the experiments, the highest increase in RNF168 expression was the 100ng/ml at 
140% in comparison to the control. The biggest decrease was by 82% in comparison to 
the control (Figure 3.5.2 (a)) at 1ng/ml IFN-! concentration.  
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Figure 3.5.3: Combined data of 3 experiments of RNF168 expression relative to 
control for 24 hours IFN-!  stimulation of A549 cells. Data was combined together 
into a graph to provide a clear comparison between experiments. 
 
 
 
Two experiments show an increase in RNF168 expression with increasing IFN-! 
concentration (Figure 3.5.3 experiment 1 and 2)). However, there is a decrease of 82%  
(experiment 1) and 64 % (experiment 2) in RNF168 expression between control and 
IFN-! 1ng/ml for the same 2 experiments (Figure 3.5.3). The highest level of IFN-! 
expression for the same 2 experiments occurred at 100ng/ml IFN-! concentration 
(Figure 3.5.3). These values were 146% and 39% greater than the control (Figure 3.5.3). 
In experiment 3 RNF168 expression was lower in IFN-! stimulated samples.  
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Figure 3.5.4: Mean level of RNF168 expression for A549 cells stimulated with IFN-
! . The mean values from all 3 experiments were calculated and standard error of the 
mean represented as error bars to show the accuracy of the values obtained.  
 
As the concentration of IFN-! increases, the level of RNF168 expression increases 
(Figure 3.5.4). The lowest value with respect to the control is at 1ng/ml where there is a 
67% decrease in RNF168 expression in comparison to the control (Figure 3.5.4). The 
highest value is at 100ng/ml where RNF168 expression is 40% greater than the control 
(Figure 3.5.4). The value that is least accurate is at 100ng/ml as it has the largest 
standard error of the mean (Figure 3.5.4). 
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3.7 Western Blot Data: The Effect of Duration of Interferon beta stimulation 
on RNF168 expression  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.5: RNF168 expression for A549 cells stimulated IFN-!  for 0, 2, 4, 6, 24 
and 48 hours with paired controls. A549 cells grown in a 24-well plate were 
stimulated with IFN-! at 50ng/ml concentration for time points 0, 2, 4, 6, 24 and 48 
hours. 0 hour was taken to be the starting control where cells were not stimulated with 
IFN-! and were harvested immediately after all of the other wells had been stimulated. 
For every other time point there was a paired control of cells that had not been 
stimulated. The protein from these samples was harvested at these time points and used 
to run a western blot. The western blot images underwent densitometry analysis using 
ImageJ software.  
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Both control and IFN-! stimulated samples showed an increase in the expression of 
RNF168 in comparison to the 0 hours control (Figure 3.5.5). This was most evident 
around 4, 6 and 24 hours (Figure 3.5.5). The lowest level of RNF168 expression was at 
0 hours at 0.59 (Figure 3.5.5). The highest level of IFN-! expression was at 4 hours at 
3.98 (Figure 3.5.5). The biggest difference between control and IFN-! stimulated 
samples was seen at 4 hours where the IFN-! stimulated sample was more than 2 fold 
greater than the 4 hour control (Figure 3.5.5). In both the IFN-! and control samples 
there was a decrease in RNF168 expression at 48 hours in comparison to 24 hours 
(Figure 3.5.5). The highest level of RNF168 expression for stimulated samples was at 4 
hours whereas for control samples the highest level was at 6 hours. 
 
3.8 Western Blot Data: The Effect of Duration of PolyI:C stimulation on 
RNF168 Expression 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.6:  RNF168 expression for cells stimulated with polyI:C for 0,2, 4, 6, 24 
and 48 hours. A549 cells were grown in a 24-well plate and stimulated with polyI:C. 
The protein from these cells was harvested at 0, 2, 4, 6, 24 and 48 hours. In this 
experiment there were no paired controls for each time point. 0 hours was taken to be 
the starting control where cells were not stimulated with polyI:C and were harvested 
immediately after other samples had been stimulated. The protein from these blots was 
used to run a western blot. The images were analysed for densitometry using ImageJ 
software.  
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The lowest level of RNF168 expression was at 0 hours at 0.71 (Figure 3.5.6). The 
highest level of RNF168 expression was at 2.83 at 6 hours (Figure 3.5.6). As the 
duration of polyI:C stimulation increases up to 6 hours, the level of RNF168 expression 
also increases (Figure3.5.6). There is a considerable decrease in RNF168 expression 
thereafter at 24 hours (Figure 3.5.6). However, there is an increase after 24 hours with 
the levels of RNF168 returning to levels comparable to 6 hours at 48 hours (Figure 
3.5.6). 
3.9 Palivizumab and CXCL5 Data  
3.9.1 The Effect of Palivizumab on RNF168 Expression for A549 cells infected with 
RSV MOI 
Samples from the same experiment were used when measuring RSV N gene expression 
and RNF168 expression (Figure 3.5.7 and Figure 3.5.8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.7: RSV N gene expression for A549 cells infected with RSV and treated 
with palivizumab. A549 cells were grown in a confluent 24-well plate. Of the 3 wells 
containing A549 cells, 1well was used as a control and another infected with RSV MOI 
1:1.  The third well was infected with RSV MOI 1:1 but palivizumab was added.  The 
RNA from these samples was taken to run real-time PCR.  
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The lowest level of RSV N gene expression was the control at 1.23 (Figure 3.5.7). The 
highest level of RSV N gene expression was the RSV infected cells at 19.76 (Figure 
3.5.7).  In comparison to this sample, the cells that were RSV infected with palivizumab 
added had far lower levels of RSV N gene expression (Figure 3.5.7).  
  
3.9.2 The Effect of Palivizumab on RNF168 Expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.8: RNF168 expression for A549 cells infected with RSV and treated with 
palivizumab. A549 cells were grown in a confluent 24-well plate. Of the 3 wells 
containing A549 cells, one well was used as a control and another infected with RSV 
MOI 1:1. The final well was infected with RSV MOI 1:1 but palivizumab was added.  
The protein from the cells was harvested to run a western blot.  
 
 
The control has the highest level of RNF168 expression at 0.24 (Figure 3.5.8). The 
sample with RSV and palivizumab has the lowest level of RNF168 expression at 0.06 
(Figure 3.5.8). 
?@A49;!!
=!=F=8!
=F4!=F48!
=F5!=F58!
=F6!
@G! ?CD! ?CD!J.%0/Q/ROL%S!
5'
4'
*$)
<$!
D
(B
I
L
$,
-.
/'
00
1)
%
$
!
'*
23
14
'$
3)
$!
H2
:3
1%
$$$
"9R032%:'0$G++'+$3)$GSTU$:'**0$>D=E$:)%3/)*@$$
!H>I&/$!@G!!!!?CD!!?CD!J.%0/Q/ROL%S!
!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%$!"()%&'(*+%,%$!!!!!!!!!!!!!!!!!!!!-.'/0!/$!1'/02!3(%0&'!!
! 495!
3.9.3 The Effect of RSV Infection on CXCL5 Concentrations  
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.5.9: Concentration levels for CXCL5 for A549 cells infected with RSV for 
0, 2,4, 6, 24 and 48 hours. A549 cells were grown in a 24-well plate and infected with 
RSV at a MOI of 1:1. There were paired controls for 2, 4, 6, 24 and 48 hours. The 
supernatant was taken from these infected cells and controls at 0, 2, 4, 6, 24 and 48 
hours time points to run a CXCL5 Sandwich ELISA. 0 hour was taken to be the starting 
control where cells were not infected with RSV and were harvested after the samples 
had been infected. 
 
As time increases the concentration of CXCL5 increases in both infected and non-
infected samples (Figure 3.5.9). RSV infected samples have a greater CXCL5 
concentration than their paired control for all time points. The lowest concentration of 
CXCL5 is 250.62 pg/ml for the 0 hours control (Figure 3.5.9). The highest CXCL5 
concentration is 24103.79 pg/ml for the 48 hours RSV infection (Figure 3.5.9).  
 
The biggest difference between control and infected samples is at 24 hours where the 
infected sample is 8574.59 pg/ml greater than the control (Figure 3.5.9). Overall the 
biggest difference in CXCL5 concentration between infected and control samples occur 
at 24 and 48 hours (Figure 3.5.9).  
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4. Discussion 
4.1 Evaluation of Results 
 
The mean 4 and 24 hour RSV results for real-time PCR, IL-8 and IL-6 suggest that all 
infections of A549 cells were carried out accurately (Figures 3.1.3, 3.1.6, 3.1.9, 3.2.8, 
3.2.9 and 3.3.1). Mean values show that RSV infected cells had higher levels of RSV N 
gene expression and concentrations of IL-6 and IL-8 (Figures 3.1.3, 3.1.6, 3.1.9, 3.2.8, 
3.2.9 and 3.3.1). The RSV infection time course experiment provided evidence showing 
that increase duration of infection increased RSV replication (3.3.8). The differences 
between 4 hours RSV infected samples to the control were statistically significant 
(p<0.05) for IL-6 concentrations (MOI 1:1, p=0.04) (Figure 3.1.6), IL-8 concentrations 
(MOI 1:1,p= 0.03) (Figure 3.1.9) but not RSV N gene expression (MOI 1:1, p= 
0.09)(Figure 3.1.3). This could be due to the samples sizes being relatively small. As 
result, more repeat experiments for 4 and 24 hours RSV infection could be carried out. 
Comparisons between the concentration levels of IL-8 in the RSV prep and total IL-8 
concentration levels show that the total concentration of IL-8 is greater (Figure 3.2.1). 
This shows that A549 cells are producing IL-8 in response to RSV infection.  
 
The results from 4 hours RSV infection of A549 cells suggests that RSV causes an 
increase in RNF168 expression (Figure 3.2.4). It could be inferred that antiviral defence 
associated with RNF168 is greatest at 4 hours RSV infection when the MOI is 1:1 
(Figure 3.2.4). The increase seen in 4 hours RSV infected samples in comparison to the 
control was not statistically significant (MOI 0.5 p=0.11, MOI 1:1 p=0.13) (Figure 
3.2.4). This may have been due to the relatively small sample size. In comparison, 24 
hours RSV infection showed that MOIs 0.25:1 to 1:1 caused a decrease in RNF168 
expression, which was not statistically significant (MOI 1:1, p=0.14) (Figure 3.5.4). The 
significance and reliability of this finding could increase if this experiment were 
repeated.  
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This result seen at 24 hours RSV infection was supported by the RSV time-course 
experiment which showed that RNF168 expression decreased in comparison to the 
control at 24 hours for RSV MOI 1:1 (Figure 3.4.1). Measuring RSV N gene expression 
implies that greater viral replication occurs after 24 hours (3.3.8). Therefore, at 24 hours 
RSV infection MOI 1:1, RSV could be overcoming the antiviral defence of RNF168 
because there are too many virus particles per cell at a higher RSV MOI.  
 
The IFN-! data shows that there is greater RNF168 expression at 4 hours with higher 
concentrations of IFN-! (Figure 3.4.4). This finding was not statistically significant 
(IFN-! 50ng/ml p=0.14, 100ng/ml p=0.17) (Figure 3.4.4) but could be more significant 
if more experiments were repeated. These findings are supported by an IFN-! time-
course experiment where the biggest difference between IFN-! stimulated and control 
samples was at 4 hours (Figure 3.5.5). Given that IFN-! is released from A549 cells as 
an innate immune response to RSV it could be proposed that IFN-! is a trigger for 
RNF168 expression. 
 
When analysing the mean values for 24 hours IFN-! stimulation, lower concentrations 
of 1ng/ml IFN-! decrease RNF168 expression in comparison to the control (p=0.25). In 
comparison, higher IFN-! concentrations increased RNF168 expression (p=0.60). 
Repeat experiments could increase the reliability and significance of these findings. 
Higher concentrations of IFN-! could be linked to increased RNF168 expression at 4 
hours (Figures 3.2.4 and Figure 3.4.4). It could be concluded that the concentration of 
IFN-! is a factor that has the potential to affect the level of RNF168 expression. 
Furthermore, these findings may emphasise that time is a factor affecting expression of 
RNF168 by IFN-! stimulation.  
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The 4 hours RSV and IFN-! data suggest that IFN-! may play a role in increasing 
RNF168 expression. This is based on IFN-! concentration 100ng/ml and RSV MOI 1:1 
increasing RNF168 expression (Figures 3.2.4 and Figure 3.4.4). 24 hours RSV data 
suggest that the number of viral particles possibly due to replication overcomes the level 
of RNF168 expression regardless of IFN-! concentration (Figures 3.3.4, 3.3.8 and 
3.5.4). The findings with respect to the 24 Hours experiment have led to the following 
hypothesis regarding the RSV MOI effect on RNF168 expression (Figure 3.2.4).  
 
At 24 hours when the RSV MOI is low there are very few virus particles per cell. The 
virus particle is detected by A549 cells, which increase RNF168 expression and 
increase IFN-! production. This leads to the release of IFN-! from A549 cells and an 
increase in RNF168 expression. However, the cell, which the virus particle attaches to, 
experiences a decrease in RNF168 expression as its antiviral defense is overcome. 
Therefore, when there is a low RSV MOI at 0.025:1 there will be more cells that are not 
attached to viral particles and expressing RNF168 (3.2.4) (Figure 4.1). However, when 
the MOI is high at 1:1, there will be more virus particles per cell, which means that 
more cells will experience a decrease in RNF168 expression (Figure 4.2). This theory 
can apply to duration of infection as viral replication could exceed cell growth leading 
to a similar effect. 
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Figure 4.1: Theory behind lower RSV MOI 0.025:1 at 24 hours and effects on 
RNF168 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Higher MOI of RSV infection of A549 cells. 
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The other major factors affecting RNF168 expression is time. The amount of viral 
replication increases as time increases. At the same time it also true that cell growth and 
cell death occurs. This is shown by the PCR data, which highlights RSV N gene 
expression increasing by approximately 30 fold from 6 to 24 hours RSV infection 
(Figure 3.3.8). Therefore, at 24 hours, the increased viral replication primarily could 
contribute to decreased RNF168 expression. The finding in the 24 hours RSV MOI 
titration experiment are supported by the RSV time-course experiment where the 
biggest decrease in RNF168 expression was seen at 24 hours for RSV infected samples 
in comparison to the 24 hours control. However, it should be noted that cell death could 
contribute to the lower RNF168 expression, as this is more likely for longer time points. 
Furthermore, it could be that RSV has reduces cell growth and through replication leads 
to less cells being capable of expressing RNF168.  
 
There was an indication that polyI:C increased RNF168 expression over an increased 
duration of cell stimulation with the highest levels of expression seen at 6 hours (Figure 
3.5.6). In all samples other than the 24 hours control there was an increase in RNF168 
expression in comparison to the control (Figure 3.5.6). It could be assumed that the 
result at 24 hours was an anomaly (Figure 3.5.6). Regardless of whether this was true, 
stimulation of polyI:C has suggested the TLR3 receptor may play a role in the pathway 
leading to RNF168 expression. PolyI:C has a role in stimulating type 1 interferon 
production. Therefore, interferon could be having an indirect on RNF168 expression 
(165). To reliably establish that there is a significant relationship between polyI:C and 
RNF168 expression this polyI:C experiment must be repeated. 
 
The PCR data from the palivizumab experiment suggests that the palivizumab used is 
effective at reducing the RSV N gene expression indicative of palivizumab blocking 
viral infection (Figure 3.5.7). A western blot was carried out on the same samples with 
the purpose of showing that it was RSV that was affecting RNF168 expression and not 
another factor present in the RSV prep or the media in which the A549 cells were 
grown. If this were correct the level of RNF168 expression in the palivizumab sample 
would be comparable to the control rather than the sample infected with RSV MOI 1:1. 
Results indicated that RNF168 expression was affected by another factor than RSV 
(Figure3.5.8).  
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This was because the level of RNF168 expression in the palivizumab treated sample 
was lower than the RSV only treated sample (Figure 3.5.8). The protein loading 
represented by !-actin expression was uneven with the palivizumab sample having the 
least amount (Figure 3.5.8). If protein in the palivizumab treated sample had been equal 
to the other samples it may have been possible that RNF168 expression would have 
been stronger for the palivizumab treated sample. This may have affected the RNF168 
expression value obtained despite a relative ratio being calculated. To verify these 
findings this experiment must be repeated before any other RSV experiments are carried 
out. 
 
The findings from this investigation suggest that RSV affects RNF168 expression. 
However, to confirm that RSV is responsible for RNF168 expression the Western blot 
experiment with palivizumab will have to be repeated. This must show that RNF168 
expression is at a relatively similar level to the control, for the palivizumab treated 
sample. If this experiment is successful, further experiments must be carried out with 
interferon, RSV and polyI:C. Only then can experiments associated with existing 
literature be carried out to determine if the mechanism by which RNF168 expression is 
being regulated by RSV is similar to herpes simplex virus type 1 (HSV-1) (121). 
 
4.2 Comparison to Existing Literature  
RSV at an MOI of 1:1 decreased the level of RNF168 expression at 24 hours in 
comparison to the control. This supports the previous work that when RNF168 was 
knocked down, RSV N gene expression increases suggesting that RNF168 has an 
antiviral defense role in RSV. 
 
A HSV-1 paper showed that RNF168 had an antiviral defense role in recruiting repair 
factors to the site of DSBs by functioning as an E3 ligase and modifying histone 
proteins.  The paper concluded that a HSV-1 protein ICP0 functioned as an E3 ligase 
causing the degradation of RNF168 by ubiquitination(121). HeLa cells underwent 
infection with wild type (WT) HSV-1. The WT showed a decrease in RNF168 
expression at 2 hours post-infection with a MOI of 5:1 (Figure 1.1.3) (121). Similar 
results were seen when A549 cells were infected with RSV in a RSV time-course 
experiment, which noted a decrease in the RSV infected sample at 2 hours in 
comparison to the control. 
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 At 2 hours a MOI titration experiment could be done to investigate effects on RNF168 
expression in detail at 2 hours. The RSV time-course experiment showed a decrease at 
all other time points in comparison to the control. To gain a better understanding of the 
relationship between duration of infection and RNF168 expression titration experiments 
could also be done for time points between 4 and 24 hours such as 12 hours.  
 
The biggest decrease in RNF168 expression due to RSV occurred at 24 hours at MOI 
1:1 as shown by the 24 hours RSV titration experiment. These findings were supported 
by the RSV time-course experiment where the biggest decrease in the infected sample 
in comparison to the control occurred at 24 hours. Hence, in comparison to HSV-1, a 
lower viral MOI causes a significant decrease in RNF168 expression over a longer 
period of time as there is less virus particles per cell for the RSV experiments meaning 
that time must be allowed for viral replication. 
 
Another possible explanation could be that the cell types in these investigations were 
different and that other factors could be involved such as the rate of cell replication and 
growth in relation to the number of viral particles.  Both HSV-1 and RSV have different 
processes of replication with HSV-1 virus particle replicating in the nucleus allowing it 
to have a direct effect on histones. In comparison, RSV replicates in the epithelial 
cytoplasm and therefore any modification of histones by RSV could be a result of 
changes occurring in the cytoplasm (121).   
 
The primary focus of the HSV-1 experiment was ICP0, an immediate early gene protein 
that is the essential to lytic HSV-1 viral replication. Results from this paper showed that 
it was specifically ICP0 that caused degradation of RNF168 E3 ubiquitin ligase as no 
significant changes in RNF168 expression were seen with ICP0 null virus (121). RSV 
does not have an ICP0 protein present in its viral structure. Instead there may be other 
proteins in viral structure that may exhibit E3 ligase activity, playing a similar role to 
ICP0. For example, nonstructural protein 1 (NS1), which is found in the cytoplasm and 
the nucleus during RSV infection, was found to influences HOX gene expression 
through monoubiquitination histone H2B of the elongin cullin E3 ligase activity (71). 
Protein such as these could be identified and investigated further to see if they have a 
direct influence on RNF168.  
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To determine that ubiquitination of histone H2A was implicated in the role of RNF168 
in antiviral defense a HSV-1 WT time course was carried out for ubiquitinated H2A 
(uH2A) expression. This showed a loss of ubiquitinated H2A at 2 hours post-infection 
(Figure 1.1.3) (121). To show that RSV is causing histone ubiquitination a RSV 
infection time-course could be run with samples used for a Western blot for uH2A. 
Based on the RSV results obtained so far it could be hypothesised that loss of 
ubiquitinated H2A could occur at 24 hours, as this was lowest level of RNF168 
expression seen. 
 
 
The protein Ubc13 is used as a conjugating enzyme to ubiquitinate H2A. The HSV-1 
paper found that there were no decreased levels of Ubc13 during the time-course of 
viral infection. UBc13 investigation could be carried out as a time-course experiment of 
RSV infection. The results could help to determine the mechanism by which RSV is 
affecting RNF168 expression and whether the process of ubiquitination is involved 
(121).  
 
To verify that RNF168 was undergoing proteasome-mediated degradation, HSV-1 
experiments were carried out with proteasome inhibitor. This showed that the 
proteasome inhibitor prevented the degradation of RNF168 for the HSV-1 paper (121). 
A similar experiment could be carried out with RSV infected cells. If the findings were 
similar to that seen in the HSV-1 paper then it would provide support that the changes 
in RNF168 expression occurring could be due to ubiquitination.  
 
 
Experiments were carried with IFN-! and polyI:C found changes in RNF168 
expression. Both of these stimuli were not used in the HSV-1 paper. There is limited 
literature available regarding the interaction of IFN-! and polyI:C with RNF168. 
However, this investigation does provide new evidence that such a relationship does 
exist. More experiments with polyI:C must be carried out to provide detailed evidence 
that it is affecting RNF168 expression. To show that it is IFN-! having a direct effect on 
RNF168, experiments must be carried out with anti-interferon.  
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If the findings of these experiments support the results already obtained, then there will 
be more evidence about how the mechanism by which RSV affects RNF168 expression 
could differ to HSV-1.   
 
Previous work on CXCL5 showed that CXCL5 expression was highest in RSV infected 
samples at 6 hours. From the results obtained it was clear that the concentration of 
CXCL5 was greater than the control at 6 hours. However, the biggest increase in 
CXCL5 in infected samples in comparison to the control at the same time point was 
seen at 24 and 48 hours. Therefore, the data provides supporting evidence that CXCL5 
could be involved in early neutrophil recruitment during RSV infection. However, this 
experiment needs to be repeated to provide detailed evidence of the relationship 
between duration of RSV infection and the concentration of CXCL5. 
 
 
4.3 Future Work Priorities 
 
The time allowed to complete this project was only one year. If there were more time 
more experiments would have been carried out to investigate how RSV affects RNF168 
expression.  These experiments are discussed in this section. 
 
The data from the palivizumab experiment indicated that RSV was not the primary 
component causing a decrease RNF168 expression. This was because the A549 cells 
stimulated with RSV (MOI 1:1) and palivizumab for 24 hours showed a decrease in 
RNF168 expression in comparison to the control. It was expected that RNF168 
expression in this sample would be equal to the control, as the RSV has been neutralised 
by the palivizumab. To validate these findings this experiment will have to be repeated 
at least two further times.  Results will include RSV N gene expression and Western 
blot data available for each set of samples. If the results suggest that RSV is directly 
affecting RNF168, then other experiments can be carried out to investigate this 
relationship in further detail.  
 
Of the 24 hours RSV MOI titration experiments carried out, only one experiment had 
PCR and ELISA data available for the same sample used to run a western blot.  More 
repeat experiments with RSV N gene expression, IL-6 and IL-8 data for 24 hours RSV 
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MOI titration could be carried out to further increase the reliability of any proposed 
relationship between RNF168 expression and RSV.    
 
An experiment was carried out to show that the A549 cells were producing IL-8 and 
that the IL-8 result recorded by IL-8 Sandwich ELISA was not due to the RSV prep 
added. This experiment could be done for IL-6 to show that A549 cell are releasing IL-6 
in response to RSV infection. 
 
Given that RSV MOI 0.025:1 showed an increased RNF168 expression in comparison 
to the control at 24 hours, a time course experiment involving RSV MOI 1:1 could be 
done. The time points would be 0, 2, 4, 6, 24 and 48 hours where there would be a 
control for each time point.  0 hour would be a starting control where the cells would be 
harvested immediately after all other samples had been infected with RSV. The 
experiment would be repeated 3 times. This would provide evidence of how a lower 
RSV MOI affects RNF168 expression with respect to duration of infection. RSV N 
gene expression, IL-6 and IL-8 data would also be obtained for all samples.  
 
To provide a more detailed and accurate interpretation of a relationship between 
RNF168 and duration of RSV infection more RSV time course experiments must be 
carried out. A preliminary experiment was carried out which only gave data between 0 
and 24 hours. The future experiments would involve RSV infection for 0, 2, 4, 6, 24 and 
48 hours with controls for each time point where 0 hour is a starting control. This 
experiment would be carried out at least 3 times with RSV N gene expression, IL-6 and 
IL-8 data available for all samples. Carrying out this experiment would lead to a reliable 
evaluation of the relationship between RNF168 expression and duration of RSV 
infection.  
 
Only 1 IFN-! time course experiment has been carried out. This should be repeated to 
provide reliable and accurate evidence regarding the relationship between duration of 
IFN-! stimulation and RNF168 expression. Stimulation should be carried out with 
50ng/ml, as this was the concentration where RNF168 expression was highest in 
comparison to control. This was also the concentration used in the original IFN-! time-
course experiment. 
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An experiment must also be done with anti-interferon beta. The function of anti-
interferon beta is to neutralise the effects of IFN-!. IFN-! and anti-interferon beta will 
be added to A549 cells for 4 and 24 hours. If the level of RNF168 expression in samples 
is comparable to the control then it could be concluded that IFN-! stimulation has a 
direct effect on RNF168 expression. This is because anti-interferon has blocked the 
effect that IFN-! stimulation has on RNF168 expression. 
 
 
A single experiment regarding polyI:C stimulation was carried out. This was a time-
course experiment and needs to be repeated at least 2 further times. PolyI:C titration 
experiments need to be carried out at 4 and 24 hours. A459 cells will be stimulated with 
different concentrations of polyI:C and harvested at 4 and 24 hours. Experiments will be 
carried out a minimum of 3 times for both time points. The purpose of this experiment 
will be to establish the effect that different concentrations of polyI:C have on RNF168 
expression with respect to each time point. Furthermore, titration experiments at 4 and 
24 hours may provide more evidence that TLR3 is implicated in the mechanism 
regulating RNF168 expression.  
 
With regards to the quality of western blot data it was clear that the protein loading was 
uneven as indicated by the expression of !-actin for each sample in some experiment. A 
technique that could have been implemented in the future could be the use of the 
Bradford protein assay. This involves measuring the concentration of protein in each 
sample before loading the protein into a western blot gel. Calculations can then be done 
to find out the correct amount of protein that needs to be loaded for each sample to get 
even loading across all samples. A Bradford assay was not done because time taken to 
do one would have limited the amount of data that could be taken from experiments.  
An alternative to a Bradford assay, samples were re-run adjusting for protein loading 
based on the first western blot image and the amount of protein loaded to get this image. 
However, if a Bradford assay could be done in the future if more cases of uneven 
loading arise. 
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Previous work on CXCL5 showed that CXCL5 expression was highest in RSV infected 
sample at 6 hours. From the results obtained it was clear that the concentration of 
CXCL5 was greater than the control at 6 hours. However, the biggest increase in 
CXCL5 in infected samples in comparison to the control at the same time point was 
seen at 24 and 48 hours. Therefore, the data provides supporting evidence that CXCL5 
could be involved in early neutrophil recruitment during RSV infection and may have a 
bigger impact on neutrophil recruitment at later time points of infection. However, 
repeat experiments need to be carried out in order to provide detailed evidence of the 
relationship between the duration of RSV infection and the concentration of CXCL5. 
5. Concluding Remarks 
 
This investigation suggests that RSV affects RNF168 expression. However, before any 
further RSV experiments are done the experiment involving palivizumab must be 
repeated to show that RSV affects RNF168 expression and not any other factor. This 
investigation suggests that RNF168 is affected by RSV MOI infection at 4 hours and 24 
hours. Results imply that MOI of RSV and duration of infection are factors in 
influencing the level of RNF168 expression. However, to increase the reliability and the 
significance of results, RSV, IFN-! and polyI:C experiments should be repeated to 
increase the sample size.   
 
The findings from this investigation also show that IFN-! and polyI:C may be 
implicated in the mechanism by which RSV affects RNF168 expression and that this 
mechanism may differ to that demonstrated in the HSV-1 paper. Nevertheless, 
experiments similar to the HSV-1 paper with uH2A and protease inhibitor should be 
done to confirm whether ubiquitination is involved.  Furthermore, to provide evidence 
that IFN-! is affecting RNF168 and not any other factors experiments must be done 
with anti-interferon. 
 
Results from the CXCL5 experiment supports previous findings that this cytokine is 
expressed more at 6 hours RSV infection in comparison to the control. However, this 
experiment has been carried out once and will have to be repeated to provide more 
evidence of a relationship between duration of RSV infection and CXCL5 expression.  
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